[{"text": "PREMIUM Amylyx Pharmaceuticals Says FDA Lifts Clinical Hold on Phase 1 ALS Study MT Newswires Tue, Jan 21, 2025, 5:28 PM 1 min read In This Article: AMLX -6.30% Amylyx Pharmaceuticals (AMLX) said Tuesday that the US Food and Drug Administration has lifted a cli PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AMLX", "date": "2025-01-21T14:28:57+00:00", "sentiment": {"score": 0.17674642987549305, "confidence": 0.1882219910621643, "probabilities": {"positive": 0.1882219910621643, "negative": 0.011475561186671257, "neutral": 0.8003024458885193}}, "embedding": [-0.1417599767446518, -0.2572493851184845, 0.12026885151863098, 0.03259613737463951, 0.07129308581352234, -0.09306485950946808, -0.12888748943805695, -0.018905598670244217, 0.09072981774806976, -0.1069910004734993, -0.019133614376187325, 0.27935531735420227, 0.037555351853370667, -0.04411705955862999, -0.05455445870757103, 0.07319863140583038, 0.06547143310308456, -0.11506447196006775, -0.05319550633430481, 0.19513708353042603, 0.00016371482342947274, 0.03256060183048248, 0.01627100072801113, 0.08856010437011719, -0.030911102890968323, 0.04092203453183174, -0.15359829366207123, -0.05163806676864624, 0.09994636476039886, -0.014130626805126667, 0.04574815183877945, 0.13541194796562195, 0.11156727373600006, -0.10125316679477692, 0.036248933523893356, -0.01162626501172781, 0.008716728538274765, -0.10365017503499985, -0.04460610821843147, 0.07547453045845032, 0.12460280954837799, -0.18781450390815735, -0.13370276987552643, -0.044014301151037216, -0.03008531592786312, -0.260016530752182, -0.13061709702014923, -0.047217655926942825, 0.047715384513139725, 0.18780867755413055, -0.06520447134971619, -0.26932162046432495, 0.09366344660520554, -0.10279496014118195, -0.0071443067863583565, 0.14981777966022491, -0.1347905993461609, -0.05172262713313103, 0.007723513524979353, 0.01947726495563984, -0.07411815971136093, -0.006506197154521942, 0.029384415596723557, 0.13941186666488647, -0.0856063961982727, 0.10355977714061737, -0.020004482939839363, -0.04730591922998428, -0.016099704429507256, -0.18878880143165588, -0.07060699164867401, 0.006056925281882286, 0.08466459065675735, 0.030468473210930824, 0.22219854593276978, 0.16531287133693695, 0.1759990155696869, -0.10567625612020493, 0.18571771681308746, -0.11691450327634811, -0.03200903162360191, -0.19364885985851288, 0.12213874608278275, -0.04628347232937813, 0.06558887660503387, -0.06162162125110626, 0.09087692946195602, 0.010918953455984592, -0.09867174923419952, -0.09781183302402496, 0.1743764728307724, -0.07657285779714584, -0.006442508660256863, 0.0390067957341671, -0.019637515768408775, -0.03958125784993172, -0.20182882249355316, -0.0806654691696167, -0.03890546038746834, 0.02734898030757904, -0.01782669872045517, 0.09961996972560883, -0.03796748071908951, -0.06995592266321182, -0.1481107473373413, -0.20445753633975983, 0.10712995380163193, 0.02671569213271141, -0.0699603334069252, 0.07624651491641998, 0.056838952004909515, 0.03475016728043556, 0.23544631898403168, -0.11805076897144318, -0.029139913618564606, 0.26639464497566223, -0.19868947565555573, 0.026806458830833435, 0.2518472671508789, -0.17840544879436493, -0.041036542505025864, -0.03096453845500946, 0.0009321416146121919, -0.07102256268262863, 0.1408814638853073, 0.13313670456409454, -0.10047735273838043, 1.2810660862168126e-32, -0.09753253310918808, 0.09999148547649384, 0.09055984765291214, -0.033354226499795914, 0.01770058274269104, -0.11126187443733215, 0.09614499658346176, -0.12667736411094666, -0.10992835462093353, -0.17413705587387085, -0.11141764372587204, 0.184731125831604, -0.11323467642068863, 0.019067857414484024, -0.010578673332929611, -0.1960771530866623, 0.05759323015809059, 0.15871158242225647, 0.08717530220746994, 0.06074461713433266, 0.08439300209283829, -0.11033712327480316, 0.05008203163743019, -0.08029817044734955, -0.047469984740018845, 0.08705491572618484, 0.02785658836364746, 0.045607417821884155, 0.25902679562568665, 0.06982877850532532, -0.08696602284908295, 0.026993129402399063, -0.06703244894742966, -0.07883326709270477, -0.09118359535932541, 0.21111464500427246, 0.00763305276632309, 0.05000757426023483, -0.06775695085525513, -0.02866828814148903, 0.006472231820225716, 0.12576675415039062, -0.10143259912729263, -0.1019318699836731, -0.023972317576408386, -0.06992308795452118, -0.20667870342731476, -0.022147122770547867, 0.0004301678854972124, -0.1832694709300995, -0.045272357761859894, 0.09953974932432175, -0.14446449279785156, -0.07455495744943619, 0.00910919439047575, 0.095890112221241, -0.036745987832546234, -0.05470577999949455, 0.15796196460723877, 0.05981161817908287, 0.13947397470474243, 0.13354268670082092, 0.005402527749538422, -0.12857379019260406, -0.057726308703422546, 0.20596183836460114, -0.05573871359229088, -0.2237415909767151, -0.14705511927604675, 0.11871994286775589, 0.11537223309278488, -0.014992904849350452, -0.006981207057833672, 0.08444350212812424, -0.041635911911726, 0.049844056367874146, -0.025115832686424255, -0.006159195676445961, 0.1723690778017044, 0.006871949881315231, 0.10977140069007874, 0.008259924128651619, 0.09472695738077164, 0.1651376634836197, 0.06246170029044151, -0.051453545689582825, -0.06971267610788345, 0.02023453824222088, -0.08176012337207794, 0.03367238491773605, -0.049500416964292526, -0.014476414769887924, -0.016302896663546562, 0.15648360550403595, -0.1364201307296753, -1.4999332895747344e-32, -0.05367470532655716, -0.02134116366505623, 0.004217689391225576, -0.026723463088274002, -0.09448972344398499, 0.03291676193475723, 0.0017145503079518676, 0.16646015644073486, 0.2597295939922333, -0.027412747964262962, 0.15411926805973053, 0.05659949406981468, -0.04710328206419945, 0.04663110896945, 0.010705997236073017, -0.02656998485326767, -0.04155515134334564, -0.04611887410283089, -0.14229890704154968, 0.05302165821194649, 0.04571264237165451, 0.11265426129102707, -0.0013681432465091348, 0.2880864441394806, -0.08177535980939865, 0.044636521488428116, 0.09570731967687607, 0.15251846611499786, 0.01735544204711914, -0.18469172716140747, -0.18154975771903992, -0.06706942617893219, -0.19697117805480957, -0.04763621836900711, -0.12308790534734726, 0.027980946004390717, 0.01867794059216976, -0.026078127324581146, -0.07825052738189697, -0.06064970791339874, 0.08873497694730759, -0.08120815455913544, -0.11250035464763641, 0.0521540641784668, 0.08686351031064987, -0.05466507747769356, 0.07823659479618073, -0.12751425802707672, 0.10441581904888153, -0.06934373080730438, -0.17189502716064453, -0.10136480629444122, 0.21858134865760803, 0.013197135180234909, -0.027755985036492348, 0.05336003005504608, 0.054853517562150955, -0.08543703705072403, -0.03869001567363739, -0.035025566816329956, -0.0022931068670004606, 0.21708308160305023, -0.17762191593647003, -0.14211051166057587, 0.07251206785440445, 0.048864733427762985, 0.10667520016431808, -0.15282340347766876, 0.08149104565382004, -0.14881035685539246, -0.02331983856856823, 0.08758043497800827, -0.10874293744564056, -0.06883171945810318, 0.09389336407184601, 0.17014180123806, -0.21015645563602448, -0.10676820576190948, -0.035616714507341385, -0.04650374501943588, 0.0035324981436133385, -0.0270837415009737, -0.184956356883049, -0.007111990824341774, -0.014608279801905155, -0.03500853478908539, 0.1947428435087204, -0.11466468870639801, 0.018074577674269676, -0.0074187093414366245, -0.12406090646982193, -0.05546638369560242, -0.18990927934646606, 0.11338364332914352, -0.06074313446879387, -1.0019568463803807e-07, 0.08774445950984955, -0.04052019864320755, 0.14028805494308472, -0.012958086095750332, 0.1189514547586441, -0.008711909875273705, -0.05817145109176636, 0.00287631805986166, 0.000773685984313488, 0.09912067651748657, -0.04370494931936264, 0.12965692579746246, -0.013607736676931381, -0.00858386978507042, -0.10079080611467361, 0.09579271823167801, -0.035802505910396576, 0.08303669840097427, -0.019239474087953568, -0.28481343388557434, -0.1179337203502655, 0.10915165394544601, 0.23444288969039917, -0.07411210983991623, 0.1057860478758812, -0.1774083375930786, 0.010983681306242943, 0.07235337048768997, -0.046778563410043716, -0.0908726304769516, -0.11463525146245956, 0.06342346221208572, 0.0019077163888141513, 0.0044143241830170155, -0.034440573304891586, -0.08155777305364609, 0.03726108744740486, 0.1913604587316513, 0.00993959791958332, 0.07695747911930084, 0.09094837307929993, 0.0005502668209373951, 0.01734127104282379, -0.011880029924213886, 0.045999009162187576, 0.054763540625572205, -0.047619156539440155, 0.042935486882925034, 0.13415881991386414, -0.016763286665081978, 0.011118659749627113, -0.03701966255903244, 0.09158766269683838, -0.11098454892635345, -0.07193631678819656, 0.1046033427119255, -0.10900987684726715, -0.05579190328717232, 0.013546522706747055, 0.04643949121236801, 0.0436086468398571, -0.2457626461982727, 0.18827146291732788, 0.024344230070710182], "changes": {"1wk": 1.1594191681209625}}, {"text": "Intellia makes progress on HAE study; 2 more China drug deals BioPharma Dive \u00b7 Daniel Tadevosyan via Getty Images BioPharma Dive staff Wed, Jan 22, 2025, 1:00 PM 2 min read In This Article: NTLA -7.56% AVBP -3.43% AMLX -6.30% ATRA -4.05% ^YH206 +2.08% This story was originally published on BioPharma Dive . To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter . Today, a brief rundown of news involving Intellia Therapeutics and ArriVent BioPharma, as well as updates from Atara Biotherapeutics, Amylyx Pharmaceuticals and InnoCare Pharma that you may have missed. Gene editing specialist Intellia Therapeutics has dosed the first patient in a Phase 3 study of its in vivo CRISPR therapy for the rare disease hereditary angioedema, or HAE. The placebo-controlled study will test the efficacy of Intellia\u2019s drug, dubbed NTLA-2002 , in 60 adults with either Type 1 or Type 2 HAE, which can cause severe swelling attacks. The company expects to complete enrollment in the second half of this year and, pending positive results, to submit for U.S. approval in 2026. Updated follow-up data from a Phase 1/2 study will be presented this year, Intellia said Wednesday. \u2014 Delilah Alvarado ArriVent BioPharma has struck a deal with Shanghai-based Lepu Biopharma Co. to gain access to an antibody-drug conjugate for gastrointestinal cancer. ArriVent, which went public one year ago , will pay $47 million to Lepu for rights outside of China, Hong Kong, Macau and Taiwan to develop and market the ADC, dubbed MRG007. Arrivent plans to soon ask for a green light to begin clinical testing in the U.S. Lepu could receive up to $1.16 billion in additional milestone payments. \u2014 Delilah Alvarado The Food and Drug Administration has put on hold on clinical testing by Atara Biotherapeutics , including studies testing its drug Ebvallo as well as an earlier-stage CAR-T cell therapy. The hold, which halts the screening and enrollment of new patients into Atara\u2019s trials, is due to compliance issues flagged by FDA inspectors at a recent visit to a third-party manufacturing site. Those issues also led to the agency\u2019s recent rejection of Ebvallo for post-transplant lymphoproliferative disease associated with Epstein-Barr virus. Atara said it\u2019s discussed remedies with the FDA and will work \u201cexpeditiously\u201d to resolve the holds. \u2014 Ned Pagliarulo Amylyx Pharmaceuticals can move forward with a Phase 1 trial testing its experimental medicine AMX0114 for ALS after the FDA lifted a clinical hold on the study. In a statement Tuesday, Amylyx said will now work to screen, enroll and dose patients across sites in the U.S. The company, which was forced to withdraw from market an earlier ALS drug after follow-up testing showed it didn\u2019t work, plans to soon begin a Phase 1 study of AMX0114 in Canada. Early data from testing of AMX0114 could come later this year. \u2014 Ned Pagliarulo Story Continues Prolium Bioscience , a startup backed by RTW Investments , has licensed an experimental bispecific antibody from China-based developers InnoCare Pharma and KeyMed Biosciences , according to a Monday statement from the latter companies. Dubbed ICP-B02, the antibody drug binds to both CD20, a protein found on the surface of tumor cells, and CD3, an immune cell protein. Prolium will have rights to develop the drug for oncology indications in \u201cex-Asia regions\u201d and globally for indications outside of oncology. Payments to InnoCare and KeyMed could total as much as $520 million, including an unspecified upfront fee. \u2014 Ned Pagliarulo Recommended Reading The BioPharma Dive Awards for 2019 View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AMLX", "date": "2025-01-22T10:00:00+00:00", "sentiment": {"score": 0.18966992385685444, "confidence": 0.20194925367832184, "probabilities": {"positive": 0.20194925367832184, "negative": 0.0122793298214674, "neutral": 0.7857714295387268}}, "embedding": [-0.1149408221244812, -0.1300571858882904, -0.044073961675167084, -0.030240550637245178, -0.026900211349129677, -0.12828290462493896, -0.04798159748315811, 0.23578111827373505, 0.0060960883274674416, 0.06001759320497513, -0.008360441774129868, 0.09284365177154541, -0.0029717590659856796, 0.017617100849747658, -0.08401821553707123, 0.05739771947264671, -0.01534108817577362, -0.08971332013607025, -0.10599863529205322, 0.07929007709026337, -0.044210366904735565, 0.004618214443325996, 0.08487949520349503, 0.03262817859649658, -0.10888731479644775, -0.012263382785022259, 0.021556684747338295, -0.010724509134888649, -0.14850011467933655, -0.07387170195579529, 0.0424305684864521, 0.11098192632198334, -0.0049224188551306725, -0.08111999183893204, 0.059932246804237366, -0.0669194757938385, -0.0703706368803978, 0.015833191573619843, -0.05022890865802765, -0.0440981425344944, 0.06197008490562439, -0.17638826370239258, -0.10722878575325012, 0.030978510156273842, 0.05990485101938248, -0.14267419278621674, -0.04453003779053688, -0.03938382863998413, -0.00842294842004776, 0.15170389413833618, -0.21536016464233398, -0.14652085304260254, -0.009614083915948868, 0.03748951107263565, -0.06335730105638504, -0.04254652559757233, -0.06732168793678284, -0.08170114457607269, 0.032240793108940125, 0.038579825311899185, -0.03493914008140564, -0.06644582748413086, 0.018964899703860283, -0.02397812530398369, -0.005381687544286251, 0.02876303717494011, 0.09138979017734528, -0.15908309817314148, 0.06496399641036987, -0.07284007966518402, 0.10202253609895706, -0.06412854790687561, -0.026733221486210823, 0.21606338024139404, -0.06407564878463745, 0.056043822318315506, 0.14297319948673248, 0.09803200513124466, 0.22764724493026733, -0.13888145983219147, 0.11220788210630417, -0.01325897965580225, 0.14545410871505737, -0.006885077804327011, 0.011848807334899902, 0.07306713610887527, 0.001532409805804491, 0.161471426486969, 0.07489408552646637, -0.008246882818639278, 0.17288196086883545, 0.02607034333050251, -0.04193607717752457, -0.01680123805999756, 0.06025787815451622, -0.07363708317279816, 0.010593891143798828, 0.0051625631749629974, 0.0018349690362811089, 0.008939883671700954, 0.025729041546583176, 0.04345524311065674, -0.1623641401529312, -0.07202307879924774, -0.0537107028067112, -0.05037525296211243, 0.06552132964134216, -0.1101560965180397, 0.06449219584465027, 0.02353082038462162, -0.10266493260860443, 0.031547270715236664, 0.014801638200879097, -0.024419624358415604, -0.12707962095737457, 0.22467097640037537, -0.02222236804664135, 0.036234740167856216, 0.11832989752292633, -0.052643999457359314, 0.02675689198076725, -0.04313090443611145, 0.009772388264536858, -0.08087444305419922, 0.23399843275547028, 0.04199456050992012, -0.21769486367702484, 1.3264175398922995e-32, 0.03633871674537659, 0.07516153901815414, -0.03160090744495392, 0.012341653928160667, -0.07493717968463898, -0.02815525233745575, 0.06417932361364365, -0.03193606436252594, -0.14030538499355316, -0.10276608914136887, -0.1563146710395813, -0.08060470968484879, -0.017274662852287292, 0.0859617218375206, -0.0677136778831482, -0.057386189699172974, -0.05509005859494209, 0.03351772949099541, -0.14528627693653107, 0.028584342449903488, 0.08636397123336792, -0.02548465132713318, -0.008504785597324371, -0.05118994414806366, -0.09360317885875702, 0.10162443667650223, -0.09730641543865204, 0.06763029843568802, 0.16883227229118347, 0.06594957411289215, -0.14712300896644592, -0.048015058040618896, 0.07479780912399292, -0.032784659415483475, -0.03984729200601578, -0.00521416962146759, -0.03835824504494667, -0.08227911591529846, -0.035357557237148285, 0.16009414196014404, 0.03236031532287598, 0.21410852670669556, -0.09343424439430237, -0.09942208230495453, 0.11140510439872742, -0.08725705742835999, -0.10399674624204636, 0.025477172806859016, 0.00966440699994564, -0.02479584887623787, -0.047638941556215286, -0.03619762137532234, 0.007497699931263924, -0.06335018575191498, -0.004076237790286541, 0.03325045481324196, -0.14156444370746613, -0.0509323813021183, 0.17879298329353333, 0.0880538672208786, 0.05359834060072899, 0.0976819097995758, -0.005914777517318726, 0.11097787320613861, -0.04572509601712227, 0.10188515484333038, -0.071710966527462, -0.06901702284812927, -0.07014220952987671, 0.11806836724281311, 0.049942467361688614, -0.09414586424827576, 0.07060901075601578, 0.010643227025866508, -0.07317556440830231, -0.11374367028474808, 0.014790251851081848, 0.13736051321029663, 0.03102611005306244, -0.030196692794561386, 0.12164192646741867, -0.012618880718946457, 0.023778386414051056, 0.13024285435676575, -0.012475836090743542, -0.09399210661649704, -0.016571994870901108, 0.006599382497370243, -0.19787056744098663, -0.057149361819028854, 0.1303594410419464, -0.044643279165029526, -0.0075151314958930016, -0.024810995906591415, -0.019506461918354034, -1.249618085849264e-32, -0.08077376335859299, -0.026231594383716583, -0.1006585955619812, -0.02101762406527996, -0.009291643276810646, 0.14085450768470764, 0.08761955797672272, -0.03382241725921631, 0.20001007616519928, -0.07772810757160187, 0.08910711109638214, 0.048007939010858536, 0.0200029443949461, -0.08531614392995834, -0.04728345945477486, 0.025225605815649033, -0.01654847525060177, -0.09969034790992737, -0.03173115849494934, 0.07224210351705551, -0.0012921574525535107, 0.09458516538143158, -0.057787105441093445, 0.05704508349299431, 0.006726023741066456, 0.0672091692686081, 0.06408827006816864, 0.08191905915737152, 0.032747820019721985, -0.06346789747476578, -0.0755135789513588, 0.03356079012155533, -0.23764710128307343, 0.0040749963372945786, 0.009202820248901844, -0.06629740446805954, 0.05804891139268875, -0.09084439277648926, -0.021359335631132126, -0.0628688707947731, 0.0684521347284317, 0.007205698173493147, -0.024651115760207176, 0.08395304530858994, 0.02425411157310009, 0.07881786674261093, 0.02953488938510418, -0.007843287661671638, 0.12486082315444946, -0.029208485037088394, -0.02029607445001602, 0.0036164692137390375, 0.05363108590245247, 0.03233177214860916, -0.055100083351135254, -0.039781663566827774, 0.10138169676065445, -0.05419031158089638, -0.13859474658966064, 0.03034648671746254, -0.014773705042898655, 0.06504657864570618, 0.014275024645030499, -0.0021056989207863808, 0.07607629150152206, 0.18322217464447021, 0.08954284340143204, 0.02213180810213089, 0.01846085488796234, -0.16414545476436615, -0.062329668551683426, -0.07967305183410645, -0.01619657874107361, -0.10110919177532196, 0.10317246615886688, 0.10601553320884705, -0.09983550012111664, -0.05126369372010231, -0.04413212463259697, -0.0012557529844343662, 0.013423621654510498, -0.10974393784999847, 0.004509593825787306, -0.05218036472797394, 0.042057305574417114, 0.05493088811635971, -0.022019172087311745, 0.0066374423913657665, -0.0038278724532574415, -0.030223466455936432, -0.0989692211151123, -0.12043459713459015, -0.07772135734558105, 0.06166104972362518, -0.044994138181209564, -1.0073826217649184e-07, 0.1688099503517151, -0.12774339318275452, 0.0016295209061354399, -0.05685678869485855, -0.04933962970972061, -0.06684006005525589, -0.08031092584133148, 0.06845973432064056, 0.019569391384720802, 0.12891551852226257, 0.026337984949350357, 0.1950799524784088, -0.07079611718654633, -0.03529039025306702, -0.01921221800148487, 0.03241521120071411, 0.025447189807891846, 0.06468226760625839, -0.08233701437711716, -0.002282814122736454, -0.07138488441705704, 0.03678862005472183, 0.08514776825904846, -0.11641102284193039, 0.1477367877960205, -0.010266202501952648, -0.042219072580337524, 0.014804084785282612, -0.03519578278064728, -0.08158977329730988, -0.04852595925331116, -0.060175858438014984, 0.12477689236402512, 0.09076496958732605, -0.035501159727573395, -0.16981685161590576, 0.11865270137786865, 0.07940605282783508, 0.09329238533973694, 0.09500505775213242, 0.06964614242315292, 0.017746571451425552, -0.0324801504611969, -0.01353377103805542, 0.023337215185165405, -0.03333752602338791, -0.02524668537080288, -0.08665970712900162, 0.12665463984012604, -0.05929339677095413, -0.07150933891534805, 0.023094674572348595, 0.024678267538547516, -0.07051031291484833, 0.019012942910194397, 0.14426204562187195, -0.05407300591468811, -0.05915912613272667, 0.027327097952365875, -0.009957225061953068, 0.1369960904121399, -0.08624600619077682, 0.14744047820568085, 0.0831252783536911], "changes": {"1wk": -0.862068138659312}}, {"text": "Amylyx Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on AMX0114 Phase 1 Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis Business Wire Tue, Jan 21, 2025, 5:00 PM 5 min read In This Article: AMLX -6.30% \u2022 Company will move forward with trial sites across North America CAMBRIDGE, Mass., January 21, 2025 --( BUSINESS WIRE )-- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (\"Amylyx\" or the \"Company\") today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold placed on the Phase 1 clinical trial of AMX0114, an investigational antisense oligonucleotide (ASO) targeting calpain-2 for people living with amyotrophic lateral sclerosis (ALS). With the clinical hold lifted, Amylyx is now working to open U.S. sites for screening, enrollment, and dosing. The announcement comes as Amylyx expects to initiate the Phase 1 LUMINA clinical trial in Canada in the beginning of 2025. LUMINA is a multicenter, randomized, placebo-controlled, multiple ascending dose trial evaluating the safety and biological activity of AMX0114. LUMINA will also assess ALS biomarkers, including change from baseline in neurofilament light (NfL) levels. Approximately 48 people living with ALS will be randomized 3:1 to receive AMX0114 or placebo by intrathecal administration once every four weeks for a total of up to 4 doses. \"Based on several preclinical efficacy studies and what is known about the central role of calpain-2 in the process of axonal degeneration, we believe AMX0114 has the potential to be a treatment for ALS and other diseases,\" said Camille L. Bedrosian, MD, Chief Medical Officer of Amylyx. \"Calpain-2 is a well-established target in a number of neurological diseases and a protease known to cleave many substrates including neurofilament, tau, and TDP43 proteins. In addition to being considered an essential protein in the process of axonal degeneration, calpain-2 has been repeatedly linked to neurofilament biology in published studies. We are dedicated to investigating therapies to potentially treat people living with ALS, and we are excited to work with study investigators and clinical trial sites across North America to enroll participants in LUMINA.\" Amylyx continues to anticipate early cohort data from LUMINA in 2025. About AMX0114 AMX0114 is an investigational antisense oligonucleotide (ASO) targeting calpain-2 ( CAPN2 ) for the potential treatment of ALS. In preclinical studies, treatment with AMX0114 resulted in potent, dose-dependent, and durable reduction in CAPN2 mRNA and calpain-2 protein levels in disease-relevant cell models of axonal degeneration. This translated to improved neuronal survival, including in a model of TDP-43 ALS, and reductions in extracellular neurofilament light (NfL) levels across multiple disease models and paradigms of neuronal injury. AMX0114 was well-tolerated in in vivo preclinical safety studies. Story Continues About LUMINA The Phase 1 LUMINA study ( NCT06665165 ) is a multicenter, randomized, placebo-controlled, multiple ascending dose trial evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of AMX0114 in 48 adults living with ALS. LUMINA will also assess change from baseline in calpain-2 levels, neurofilament light (NfL) levels, and other pharmacodynamic biomarkers of ALS. About ALS Amyotrophic lateral sclerosis (ALS, also known as motor neuron disease) is a relentlessly progressive and fatal neurodegenerative disorder caused by motor neuron death in the brain and spinal cord. Motor neuron loss in ALS leads to deteriorating muscle function, the inability to move and speak, respiratory paralysis, and eventually, death. More than 90% of people with ALS have sporadic disease, showing no clear family history. About Amylyx Pharmaceuticals Amylyx is committed to the discovery and development of new treatment options for communities with high unmet needs, including people living with serious and fatal diseases. The Company has preclinical or clinical development programs underway in neurodegenerative, neuroendocrine, and endocrine diseases. Since its founding, Amylyx has been guided by science to address unanswered questions, keeping communities at the heart and center of all decisions. Amylyx is headquartered in Cambridge, Massachusetts. For more information, visit amylyx.com and follow us on LinkedIn and X . For investors, please visit investors.amylyx.com . Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are \"forward-looking statements\" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, Amylyx\u2019 expectations regarding: the potential for AMX0114 as a treatment for ALS and the planned initiation of a trial evaluating AMX0114 in ALS. Any forward-looking statements in this press release and related comments in the Company's earnings conference call are based on management\u2019s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: the success, cost, and timing of Amylyx\u2019 program development activities; Amylyx\u2019 ability to execute on its regulatory development plans and expectations regarding the timing of results from its planned data announcements and initiation of clinical studies; Amylyx\u2019 ability to fund operations, and the impact that global macroeconomic uncertainty, geopolitical instability, and public health events will have on Amylyx\u2019 operations, as well as the risks and uncertainties set forth in Amylyx\u2019 United States Securities and Exchange Commission (SEC) filings, including Amylyx\u2019 Annual Report on Form 10-K for the year ended December 31, 2023, and subsequent filings with the SEC. All forward-looking statements contained in this press release and related comments in our earnings conference call speak only as of the date on which they were made. Amylyx undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law. View source version on businesswire.com: https://www.businesswire.com/news/home/20250121402150/en/ Contacts Media Amylyx Media Team (857) 799-7274 amylyxmediateam@amylyx.com Investors Lindsey Allen (857) 320-6244 Investors@amylyx.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AMLX", "date": "2025-01-21T14:00:00+00:00", "sentiment": {"score": 0.3754831114783883, "confidence": 0.3897944688796997, "probabilities": {"positive": 0.3897944688796997, "negative": 0.014311357401311398, "neutral": 0.5958941578865051}}, "embedding": [-0.043751709163188934, -0.26305848360061646, 0.04547025263309479, -0.02801508456468582, 0.00296449800953269, -0.10606341063976288, -0.09137062728404999, 0.143905907869339, 0.17712821066379547, 0.058056026697158813, -0.07662009447813034, 0.21090790629386902, 0.009484192356467247, 0.07015074044466019, -0.22642549872398376, 0.10451051592826843, -0.012451019138097763, -0.04509824514389038, -0.0472404807806015, 0.1880275011062622, 0.16124281287193298, -0.02194659598171711, 0.03496725857257843, 0.08508746325969696, -0.10396285355091095, 0.09665830433368683, -0.11349338293075562, 0.02726760506629944, -0.03189021348953247, 0.04959508776664734, 0.15758737921714783, 0.20880244672298431, -0.03063335455954075, -0.0004294109530746937, -0.062124110758304596, 0.014421069994568825, -0.19240175187587738, -0.11045242846012115, -0.21852941811084747, -0.07217463850975037, 0.09141625463962555, -0.031293969601392746, -0.06778048723936081, 0.03272236883640289, 0.01192967314273119, -0.24688056111335754, -0.05899452418088913, -0.09963811933994293, 0.02853219397366047, 0.20610687136650085, 0.034656550735235214, -0.12660133838653564, 0.10863719135522842, 0.11725199222564697, 0.06798217445611954, 0.16036513447761536, -0.11190932989120483, 0.05093823000788689, 0.021800514310598373, 0.10312050580978394, -0.014249823056161404, -0.022318148985505104, 0.02315797284245491, -0.1022883877158165, 0.0148785300552845, 0.07465554028749466, -0.07647150754928589, -0.18974676728248596, -0.13137559592723846, -0.06753531098365784, -0.030679356306791306, 0.02643726021051407, 0.08997879177331924, 0.13814157247543335, 0.026587888598442078, -0.005126503296196461, 0.14807313680648804, -0.007620113901793957, 0.18090718984603882, -0.19758526980876923, 0.08274674415588379, 0.009445765987038612, 0.11206550896167755, 0.001998741179704666, 0.13850879669189453, 0.07628054171800613, 0.08969249576330185, 0.23387080430984497, -0.017704056575894356, 0.020413555204868317, 0.07636155188083649, -0.043180208653211594, 0.022171560674905777, -0.0735698938369751, 0.15378651022911072, -0.07153189927339554, -0.06448335945606232, -0.012780521996319294, 0.011014750227332115, -0.06463033705949783, 0.03486879914999008, 0.109078548848629, -0.0023740981705486774, -0.1846460998058319, -0.07013923674821854, 0.018261225894093513, 0.045173950493335724, -0.1294008195400238, -0.09467372298240662, 0.03759998083114624, 0.07462359964847565, -0.022492196410894394, 0.10813867300748825, 0.0009231511503458023, -0.029182832688093185, 0.2752995789051056, -0.08557329326868057, 0.06535132229328156, 0.19141021370887756, -0.09182184934616089, 0.053428735584020615, -0.013095628470182419, 0.11065000295639038, -0.12282121181488037, 0.20927366614341736, 0.111845001578331, -0.2398240566253662, 9.019942842683737e-33, -0.0872524306178093, -0.02116728015244007, -0.1417972594499588, 0.09678936004638672, 0.04598377272486687, -0.15228036046028137, 0.09232249110937119, 0.09118480235338211, -0.041549861431121826, -0.0932871401309967, -0.05795108899474144, 0.032954372465610504, -0.012729072943329811, 0.0789128988981247, 0.08975052833557129, -0.06990242004394531, 0.07165803015232086, -0.0686364620923996, 0.012017793953418732, -0.03850556164979935, 0.0974082201719284, -0.08893255144357681, -0.010347693227231503, -0.040611837059259415, -0.0737113431096077, 0.028207402676343918, -0.1403231918811798, 0.14303570985794067, 0.1740277111530304, -0.01556177157908678, -0.08166112005710602, -0.04815985634922981, -0.12091092765331268, 0.02577710896730423, -0.026557890698313713, 0.04913247749209404, 0.03894583880901337, -0.035435181111097336, -0.03717254102230072, 0.23149080574512482, 0.08005164563655853, 0.1512123942375183, -0.006756037473678589, -0.07379421591758728, 0.09611021727323532, -0.07706218957901001, -0.104115791618824, -0.06212791055440903, 0.09989753365516663, -0.01001894474029541, 0.05392923951148987, -0.03190463036298752, 0.04000960662961006, -0.15638329088687897, -0.08570174872875214, 0.11596286296844482, -0.16828495264053345, -0.10499811172485352, 0.1587713658809662, 0.07776820659637451, 0.004396549426019192, -0.022881250828504562, -0.06344757229089737, 0.029943961650133133, -0.08625254780054092, 0.10217178612947464, 0.05994157865643501, -0.12827496230602264, -0.21182410418987274, -0.019279977306723595, 0.012191115878522396, -0.06603824347257614, 0.24902662634849548, 0.02150065079331398, 0.01841629110276699, 0.08278881758451462, 0.12536589801311493, 0.15591369569301605, 0.06097497418522835, -0.11462979018688202, 0.023920930922031403, 0.035200685262680054, -0.1662156879901886, 0.19618040323257446, 0.018572553992271423, -0.03837437182664871, -0.0033996906131505966, -0.054000504314899445, -0.22228708863258362, 0.014221061021089554, 0.07331375777721405, -0.10927706211805344, -0.0572330616414547, 0.07392589747905731, -0.11059825867414474, -1.0949681388767637e-32, -0.13527189195156097, 0.025955118238925934, 0.053435005247592926, -0.059546299278736115, -0.11107226461172104, 0.16320765018463135, 0.25535160303115845, -0.18767425417900085, 0.21333454549312592, -0.2647451162338257, 0.12717629969120026, 0.07450513541698456, -0.008649048395454884, -0.036684662103652954, -0.028405308723449707, 0.05133805796504021, -0.17101751267910004, 0.022332120686769485, -0.11072082817554474, -0.06842533499002457, 0.14777536690235138, 0.32218191027641296, -0.05214695632457733, 0.1363193392753601, -0.002083245664834976, -0.01450885646045208, 0.12365438044071198, 0.039467912167310715, 0.044375985860824585, -0.017903298139572144, -0.19927623867988586, -0.023028366267681122, -0.14657476544380188, -0.160008043050766, -0.22000837326049805, 0.002231605350971222, -0.007356453686952591, -0.18028134107589722, -0.16606417298316956, -0.04123342037200928, 0.10044828057289124, 0.1165928989648819, -0.03734628111124039, 0.09090323746204376, 0.027107156813144684, -0.08361004292964935, -0.041369371116161346, -0.09970328956842422, 0.1428661197423935, 0.010616179555654526, -0.11707308888435364, -0.06377991288900375, -0.016366181895136833, 0.008197857066988945, -0.04125751182436943, 0.02455263026058674, 0.05388421565294266, 0.02622460387647152, -0.061300843954086304, 0.08481702208518982, -0.062058866024017334, 0.0697229728102684, 0.010965293273329735, -0.018527721986174583, 0.17193946242332458, 0.14536212384700775, 0.007051009684801102, -0.044579774141311646, 0.11310243606567383, -0.09754936397075653, -0.11422690749168396, -0.04010241851210594, -0.04915636405348778, 0.0303459744900465, 0.10424265265464783, 0.06318525224924088, -0.17200517654418945, -0.077730193734169, -0.029212821274995804, -0.07865822315216064, -0.07292699813842773, -0.027181871235370636, -0.12561549246311188, 0.08000485599040985, -0.0160371046513319, -0.052972711622714996, 0.08984234929084778, -0.016643807291984558, 0.10807236284017563, -0.09857615828514099, -0.06363341957330704, -0.13308390974998474, -0.11321145296096802, 0.1162143349647522, -0.13576430082321167, -1.0060922761567781e-07, 0.04144325107336044, -0.014539934694766998, 0.0547449067234993, -0.11230573058128357, 0.07286563515663147, -0.1259026676416397, 0.02441202662885189, 0.06966343522071838, -0.056199707090854645, 0.08973190188407898, 0.05496414005756378, 0.1906650960445404, -0.0974668562412262, -0.019000381231307983, -0.08866710960865021, 0.15341144800186157, -0.035318002104759216, 0.011002474464476109, -0.058984845876693726, -0.1692577600479126, -0.1312108039855957, 0.013901298865675926, 0.053974978625774384, -0.02328524924814701, 0.08335336297750473, -0.20275676250457764, -0.0597696378827095, 0.20243972539901733, -0.047448910772800446, -0.1462913453578949, -0.10640986263751984, 0.06992314755916595, 0.004864033777266741, -0.03540574386715889, -0.1175215095281601, -0.14961257576942444, 0.03640887513756752, 0.15952976047992706, 0.0781414806842804, 0.13637471199035645, -0.004257850348949432, -0.009266826324164867, -0.007858437485992908, -0.003626398742198944, 0.08770191669464111, 0.007276706863194704, 0.008052504621446133, 0.010618723928928375, 0.1326930969953537, -0.11992043256759644, 0.007446805015206337, 0.06314266473054886, -0.03203392028808594, -0.13449501991271973, -0.1490510106086731, 0.02157837152481079, -0.14273428916931152, 0.017700254917144775, 0.151169091463089, -0.09938301891088486, -0.030348680913448334, -0.02425473742187023, 0.11458665877580643, -0.10285675525665283], "changes": {"1wk": 1.1594191681209625}}, {"text": "PREMIUM Amylyx Pharmaceuticals Prices $60 Million Common Stock Offering MT Newswires Fri, Jan 10, 2025, 5:10 PM 1 min read In This Article: AMLX -6.30% Amylyx Pharmaceuticals (AMLX) said Friday it priced an underwritten offering of about 17.1 million c PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AMLX", "date": "2025-01-10T14:10:58+00:00", "sentiment": {"score": 0.043253906071186066, "confidence": 0.05648353323340416, "probabilities": {"positive": 0.05648353323340416, "negative": 0.013229627162218094, "neutral": 0.9302867650985718}}, "embedding": [-0.1170300543308258, -0.1540638506412506, 0.04701555147767067, 0.18820838630199432, 0.01435717660933733, -0.04752236232161522, -0.0008148623164743185, 0.11719466000795364, 0.23003266751766205, -0.0009323983103968203, -0.039981357753276825, 0.19643579423427582, 0.10543996095657349, -0.04695375636219978, -0.1419503092765808, 0.07280261069536209, 0.09665073454380035, -0.06606858968734741, -0.042372480034828186, 0.1842535436153412, -0.1329360455274582, -0.10266943275928497, -0.0027197394520044327, 0.0656609833240509, 0.16380789875984192, 0.03456186130642891, -0.11571335047483444, -0.043522242456674576, 0.034512799233198166, -0.02606598474085331, 0.011666784062981606, 0.026693468913435936, 0.14847412705421448, 0.01711057312786579, -0.021858172491192818, 0.03305003419518471, -0.11596757918596268, -0.0773511528968811, -0.07937988638877869, 0.08584459871053696, 0.12903326749801636, -0.0802350714802742, -0.19999323785305023, -0.03784932196140289, -0.11538148671388626, -0.2695261240005493, -0.08710534870624542, 0.059414543211460114, 0.13114023208618164, 0.19140329957008362, -0.09793543815612793, -0.16086314618587494, -0.03746237978339195, -0.09977748990058899, -0.0676547959446907, 0.018538299947977066, -0.2490212470293045, -0.10897637903690338, 0.08375289291143417, 0.026561351493000984, -0.008358250372111797, 0.02275991067290306, -0.006850193254649639, 0.10837903618812561, -0.07237759977579117, 0.0807703286409378, 0.03238941356539726, 0.025947097688913345, 0.07991509884595871, -0.1991156041622162, -0.011979881674051285, 0.17039823532104492, 0.07521175593137741, -0.08046557754278183, 0.06415741890668869, 0.07670222222805023, 0.2522945702075958, -0.1064712330698967, 0.1284322887659073, -0.08449269086122513, -0.05172917991876602, -0.1932680308818817, 0.08440547436475754, -0.08461782336235046, 0.14243413507938385, -0.09202828258275986, 0.2886826992034912, 0.07136216014623642, 0.07472792267799377, -0.10304291546344757, 0.1336059421300888, -0.031058067455887794, -0.04120364785194397, -0.057819511741399765, 0.01819233037531376, 0.04440708085894585, -0.20426639914512634, -0.06633026152849197, -0.11845257133245468, 0.0037235834170132875, 0.09496696293354034, 0.11637324094772339, -0.016478389501571655, -0.07730855792760849, -0.14319148659706116, -0.1450166553258896, 0.01053894218057394, 0.0822356641292572, -0.014425480738282204, 0.024143077433109283, -0.0511208139359951, -0.04657158628106117, 0.04833249747753143, -0.17561772465705872, -0.015468217432498932, 0.1193537712097168, -0.12752455472946167, -0.08887025713920593, 0.16001619398593903, -0.1429147720336914, -0.040659017860889435, -0.048649683594703674, 0.028693055734038353, 0.010504535399377346, 0.053345344960689545, 0.046657174825668335, -0.09642791748046875, 1.3090844348790433e-32, -0.060418639332056046, 0.24581389129161835, 0.023125968873500824, -0.11062134057283401, -0.005895804613828659, -0.040624283254146576, 0.14742958545684814, -0.0691060945391655, -0.22124437987804413, -0.0497765988111496, -0.19917351007461548, 0.141030952334404, -0.11161398887634277, 0.12648877501487732, 0.011900775134563446, -0.19254349172115326, 0.15975968539714813, -0.012744905427098274, 0.2732258439064026, 0.0904867947101593, 0.028299439698457718, 0.0019065509550273418, -0.023598941043019295, -0.05014697462320328, -0.0848163440823555, 0.07006950676441193, 0.03961772471666336, 0.1288863569498062, 0.17293918132781982, 0.026678983122110367, -0.10189009457826614, -0.011523677967488766, 0.025539927184581757, 0.008542414754629135, -0.01832667551934719, 0.19553445279598236, -0.08792634308338165, -0.027439391240477562, 0.11603149026632309, -0.03881141170859337, 0.03428869694471359, 0.14610563218593597, -0.11233162879943848, -0.11602034419775009, -0.07421485334634781, 0.15067917108535767, -0.05648127198219299, -0.058913201093673706, 0.07201512902975082, -0.2064826786518097, -0.018685724586248398, 0.1539371758699417, -0.18763861060142517, -0.014978836290538311, -0.1181751936674118, 0.06562002003192902, -0.07119889557361603, -0.07722742110490799, 0.2588714063167572, 0.2322050780057907, 0.044240351766347885, 0.11382517963647842, 0.09234912693500519, 0.017870480194687843, -0.10346066206693649, 0.21203608810901642, -0.047461867332458496, 0.0024472172372043133, -0.16164186596870422, 0.22926731407642365, 0.10792586207389832, -0.10684801638126373, 0.1909477412700653, -0.04242165386676788, -0.06244456395506859, 0.06753171980381012, -0.05910434573888779, -0.16265107691287994, 0.28588640689849854, 0.06758549809455872, 0.05267591029405594, 0.014594647102057934, 0.07688307762145996, 0.08959274739027023, 0.027734125033020973, -0.043109145015478134, -0.06339999288320541, 0.03586231917142868, -0.07283419370651245, 0.1385248750448227, 0.14841309189796448, 0.013560444116592407, -0.13447800278663635, 0.021496407687664032, -0.06756287068128586, -1.3822232525768245e-32, -0.04434990510344505, 0.002798103028908372, -0.023975100368261337, -0.024513941258192062, -0.24788406491279602, 0.02844025008380413, 0.06902846693992615, 0.28324946761131287, 0.19139505922794342, 0.16622725129127502, 0.14851787686347961, 0.046917080879211426, -0.15923631191253662, 0.019863242283463478, 0.004385814536362886, -0.05871177464723587, 0.057528864592313766, -0.05958911031484604, -0.010447341948747635, -0.09493236243724823, -0.12034966796636581, 0.21190494298934937, -0.0932924896478653, 0.23721195757389069, 0.05250202864408493, 0.04741004854440689, 0.06226443499326706, 0.12036271393299103, 0.04165561869740486, -0.03629474714398384, -0.14825724065303802, -0.08133324235677719, -0.1186843141913414, -0.09448764473199844, -0.17096330225467682, 0.15180239081382751, 0.11221309006214142, -0.003982883878052235, 0.026351425796747208, -0.09425877034664154, 0.06881190836429596, -0.07282178848981857, 0.030965620651841164, 0.03882550820708275, 0.1390264332294464, -0.140823096036911, -0.08603924512863159, -0.11537391692399979, 0.2168821096420288, -0.04210668429732323, -0.14975495636463165, -0.11066839843988419, 0.15869586169719696, 0.06814982742071152, -0.192057803273201, 0.08564852178096771, -0.05690925568342209, 0.07284948974847794, 0.10817322134971619, -0.10746078193187714, 0.004810982383787632, 0.24349676072597504, -0.140851691365242, -0.05216992273926735, -0.01676550693809986, 0.04376260191202164, 0.02264278568327427, -0.1424989402294159, -0.04869246482849121, -0.17345650494098663, 0.0021839053370058537, 0.0067953378893435, 0.008847366087138653, -0.16535742580890656, 0.07082238793373108, 0.1472279131412506, -0.08857756853103638, 0.004515088628977537, 0.11556431651115417, 0.04624238610267639, 0.09703698754310608, 0.06763511151075363, -0.058822520077228546, -0.05301211029291153, -0.13025455176830292, -0.14091871678829193, 0.20419436693191528, -0.019599230960011482, -0.11215340346097946, -0.01774822361767292, -0.12039323151111603, -0.12235219031572342, -0.14251552522182465, 0.056000467389822006, -0.0012236100155860186, -9.950120016810615e-08, -0.02096499502658844, -0.08663910627365112, 0.11339364945888519, -0.12414614111185074, 0.17585717141628265, -0.008134358562529087, 0.0015356405638158321, 0.049638453871011734, 0.06480516493320465, 0.2046518176794052, 0.01658034697175026, 0.0026327038649469614, -0.12965749204158783, 0.007383762393146753, -0.25557741522789, 0.006747807841747999, -0.15613718330860138, 0.005208516027778387, 0.03772889822721481, -0.23210519552230835, -0.08610408008098602, 0.22027593851089478, 0.16596971452236176, -0.06395698338747025, 0.18571755290031433, -0.10743041336536407, -0.03370700404047966, 0.05939895287156105, -0.1376127153635025, 0.04882508143782616, -0.1114567220211029, -0.03227991983294487, -0.02103554829955101, -0.032898709177970886, 0.05004052445292473, -0.009286575950682163, -0.018088122829794884, 0.1840057522058487, -0.028665028512477875, 0.036993931978940964, 0.00975237600505352, -0.14075911045074463, 0.07631765305995941, -0.009565064683556557, 0.022873330861330032, 0.011745372787117958, -0.21038970351219177, -0.08725495636463165, 0.14432743191719055, -0.11542095243930817, 0.11589789390563965, 0.0374700129032135, -0.019109023734927177, -0.11372648179531097, -0.029220085591077805, -0.08097178488969803, -0.12118642032146454, -0.05673126503825188, -0.11346235871315002, 0.035988517105579376, -0.023010022938251495, -0.3594382405281067, 0.11628709733486176, -0.007959490641951561], "changes": {"1wk": 0.0}}, {"text": "PREMIUM Amylyx Pharmaceuticals Launches Stock Offering MT Newswires Fri, Jan 10, 2025, 12:31 PM In This Article: AMLX -6.30% Amylyx Pharmaceuticals (AMLX) said late Thursday it has commenced an underwritten public offering of PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AMLX", "date": "2025-01-10T09:31:19+00:00", "sentiment": {"score": 0.05502696614712477, "confidence": 0.06605943292379379, "probabilities": {"positive": 0.06605943292379379, "negative": 0.011032466776669025, "neutral": 0.9229081273078918}}, "embedding": [-0.19572298228740692, -0.1722072809934616, 0.07403405755758286, 0.15767931938171387, 0.10478323698043823, -0.030769824981689453, -0.06263939291238785, 0.013534657657146454, 0.09009481221437454, -0.020823493599891663, 0.01054451335221529, 0.3916195333003998, 0.10999167710542679, 0.019945349544286728, -0.010885361582040787, 0.03552773967385292, 0.02730807662010193, -0.05585808306932449, -0.0038792884442955256, 0.19290155172348022, -0.05280984193086624, -0.09030919522047043, -0.0035646725445985794, 0.02718110755085945, 0.1347474306821823, 0.025331322103738785, -0.1790158748626709, -0.008988949470221996, 0.02717786282300949, -0.02588898316025734, 0.019138671457767487, -0.0012674613390117884, 0.12226112186908722, -0.068915456533432, -0.008994048461318016, 0.021137705072760582, -0.07810889184474945, -0.1180327758193016, -0.10571185499429703, 0.1418435126543045, 0.13981977105140686, -0.2169332206249237, -0.14094634354114532, 0.0039029933977872133, -0.0954730212688446, -0.27373480796813965, -0.022459596395492554, -0.014113723300397396, 0.08807799220085144, 0.15470364689826965, -0.05233296751976013, -0.2590373158454895, 0.018648002296686172, -0.10890136659145355, -0.05410417169332504, 0.027332240715622902, -0.28277331590652466, -0.04984108731150627, 0.014316905289888382, -0.07729979604482651, 0.025928841903805733, -0.00480946060270071, -0.030782058835029602, 0.11942511051893234, -0.05873272195458412, 0.17046189308166504, 0.033434584736824036, 0.13748405873775482, 0.09920914471149445, -0.29683250188827515, -0.046692248433828354, 0.1712244749069214, 0.07671806961297989, -0.021276723593473434, 0.14124004542827606, 0.12825162708759308, 0.2754285931587219, -0.05081954970955849, 0.109380342066288, -0.1482943296432495, -0.05901547148823738, -0.17748123407363892, 0.1521364450454712, -0.10106441378593445, 0.05218556150794029, -0.03709517791867256, 0.1878799945116043, 0.006360978353768587, 0.012412335723638535, -0.13686200976371765, 0.09747972339391708, -0.01332077756524086, -0.08162380009889603, -0.008235585875809193, -0.04892502725124359, -0.017132412642240524, -0.28845149278640747, -0.07385094463825226, -0.1589011400938034, 0.044561490416526794, 0.076490618288517, 0.08007331192493439, -0.07107370346784592, -0.05379440262913704, -0.043319545686244965, -0.16737663745880127, -0.06718114763498306, 0.2059440314769745, -0.018938681110739708, 0.015828892588615417, -0.020207751542329788, 0.022669292986392975, 0.1522468775510788, -0.24152018129825592, -0.04490923881530762, 0.1441202610731125, -0.2651844620704651, -0.008652894757688046, 0.2093040645122528, -0.12582553923130035, 0.01677255891263485, 0.04282202944159508, 0.039046790450811386, -0.04558949172496796, 0.1333540976047516, 0.11959434300661087, -0.024824129417538643, 1.1402138715290736e-32, -0.0961117297410965, 0.24472592771053314, 0.0783476009964943, -0.04738210141658783, 0.044025078415870667, -0.06227729469537735, 0.1412341147661209, -0.13775737583637238, -0.22977706789970398, -0.10800650715827942, -0.16879986226558685, 0.19222553074359894, -0.14515921473503113, 0.1402013897895813, 0.013366972096264362, -0.2105419784784317, 0.14013057947158813, 0.036065466701984406, 0.279371976852417, 0.09745016694068909, 0.06538663059473038, -0.08839143067598343, -0.05244375020265579, -0.040768299251794815, -0.06819592416286469, 0.1032954677939415, 0.11159785836935043, 0.10048341751098633, 0.12789767980575562, 0.08689088374376297, -0.11645394563674927, -0.044422686100006104, -0.017940456047654152, 0.005805052816867828, -0.033832233399152756, 0.15760421752929688, -0.1896335780620575, -0.06347689777612686, 0.060297444462776184, -0.13429078459739685, 0.0812222883105278, 0.04441896080970764, -0.21355518698692322, -0.06515917181968689, -0.047759346663951874, 0.14059031009674072, -0.05469192564487457, -0.0669417455792427, 0.10474972426891327, -0.1776236742734909, -0.0008152698283083737, 0.14676909148693085, -0.1671057939529419, -0.027939502149820328, -0.07710631936788559, 0.07201532274484634, -0.07342229783535004, -0.04934297129511833, 0.26194897294044495, 0.12018978595733643, 0.17651890218257904, 0.11585856974124908, 0.0659126490354538, -0.02360605262219906, -0.12984752655029297, 0.14584298431873322, 0.03679582476615906, -0.08659596741199493, -0.15097738802433014, 0.2201438993215561, 0.08116374909877777, -0.08897749334573746, 0.09604474157094955, 0.0010950200958177447, -0.045727550983428955, 0.08723552525043488, -0.1271827667951584, -0.12194370478391647, 0.29777854681015015, 0.03337354212999344, 0.09924247860908508, -0.055029354989528656, 0.11716416478157043, 0.12804023921489716, -0.055696118623018265, 0.0033050870988518, 0.026065293699502945, 0.028275230899453163, 0.018508441746234894, 0.10028951615095139, 0.051306772977113724, 0.031396932899951935, -0.11740192025899887, 0.14545738697052002, -0.03413589671254158, -1.2911421299184735e-32, -0.04085586965084076, -0.013163473457098007, -0.06622977554798126, -0.093406543135643, -0.28901195526123047, -0.008998445235192776, 0.025326330214738846, 0.2705593705177307, 0.2114102691411972, 0.12126436829566956, 0.21789447963237762, 0.033953599631786346, -0.11292815953493118, -0.03268842771649361, 0.07576192170381546, -0.06676290184259415, 0.031496018171310425, -0.1280902922153473, -0.08626427501440048, -0.029812542721629143, -0.0667785182595253, 0.146840900182724, -0.16314707696437836, 0.1948874145746231, 0.13862784206867218, -0.05425982177257538, 0.13499683141708374, 0.17477771639823914, -0.016454843804240227, -0.08480755239725113, -0.1506832391023636, -0.07271237671375275, -0.16226202249526978, -0.03724804148077965, -0.11604414135217667, 0.12355060130357742, 0.11104036122560501, 0.007516961079090834, 0.02631411887705326, -0.040490344166755676, 0.11805297434329987, -0.12826822698116302, 0.009265703149139881, 0.08711697161197662, 0.03902335464954376, -0.07051695883274078, -0.021531788632273674, -0.07656179368495941, 0.19034124910831451, -0.013614947907626629, -0.15713612735271454, -0.0683370977640152, 0.2472778856754303, -0.004465614911168814, -0.14448732137680054, 0.07135580480098724, -0.056491706520318985, -0.00873483158648014, 0.10467563569545746, -0.053692031651735306, -0.003740706481039524, 0.18798024952411652, -0.13744324445724487, -0.12572884559631348, -0.038050778210163116, -0.013539266772568226, 0.08979482203722, -0.1834123432636261, 0.022180771455168724, -0.044096801429986954, 0.021735843271017075, 0.03760623186826706, -0.07463639229536057, -0.20180034637451172, 0.05131480097770691, 0.1443946808576584, -0.10261551290750504, 0.04925859719514847, -0.0648554116487503, -0.043969929218292236, 0.04602236673235893, 0.034374989569187164, -0.05624954774975777, -0.01369746308773756, -0.06248660758137703, -0.127123162150383, 0.2628685534000397, -0.05900803580880165, -0.06712961941957474, -0.09817997366189957, -0.10376721620559692, -0.15583980083465576, -0.2662442624568939, 0.1562570482492447, -0.04813746362924576, -9.958463920156646e-08, -0.0019460123730823398, -0.08382570743560791, 0.06470900028944016, -0.132892444729805, 0.25323837995529175, 0.07669279724359512, -0.036280374974012375, -0.01393697876483202, 0.07631055265665054, 0.19064851105213165, 0.028445838019251823, -0.00956646353006363, -0.049693673849105835, -0.04300306364893913, -0.13918587565422058, 0.036464642733335495, -0.031805671751499176, 0.022857870906591415, -0.00810063537210226, -0.2792761027812958, -0.057664062827825546, 0.1325594037771225, 0.24160757660865784, -0.09495256841182709, 0.2026168406009674, -0.14228090643882751, 0.025250691920518875, -0.0011564914602786303, -0.016592862084507942, 0.021157756447792053, -0.07032830268144608, 0.04910486936569214, -0.07978397607803345, -0.099055215716362, 0.005885269492864609, 0.07697243988513947, 0.025589115917682648, 0.20097976922988892, 0.005715768318623304, 0.04248184710741043, 0.0006633625598624349, -0.11511126160621643, 0.1355227530002594, 0.025120636448264122, -0.014240597374737263, 0.020118333399295807, -0.108365997672081, -0.1379014551639557, 0.14827468991279602, -0.12090639024972916, 0.044567517936229706, -0.10191722214221954, 0.052792374044656754, -0.10329325497150421, -0.034229427576065063, 0.008667622692883015, -0.07726305723190308, -0.1262720376253128, -0.10613704472780228, 0.04850539192557335, 0.03165570646524429, -0.23628674447536469, 0.18676216900348663, -0.013373754918575287], "changes": {"1wk": 0.0}}, {"text": "Amylyx Pharmaceuticals Announces Pricing of Public Offering of Common Stock Business Wire Fri, Jan 10, 2025, 4:26 PM 4 min read In This Article: AMLX -6.30% CAMBRIDGE, Mass., January 10, 2025 --( BUSINESS WIRE )--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (\"Amylyx\" or the \"Company\") today announced the pricing of an underwritten public offering of 17,142,857 shares of its common stock at a public offering price of $3.50 per share. All of the shares are being offered by Amylyx. In addition, Amylyx has granted the underwriter a 30-day option to purchase up to an additional 2,571,428 shares of its common stock at the public offering price per share, less underwriting discounts and commissions. The gross proceeds to Amylyx from this offering are expected to be approximately $60.0 million, before deducting underwriting discounts and commissions and offering expenses and excluding any exercise of the underwriter\u2019s option to purchase additional shares. Amylyx intends to use the net proceeds from this offering, together with existing cash, cash equivalents and marketable securities, to advance preparations for commercialization and pipeline programs, for working capital and for general corporate purposes. The offering is expected to close on or about January 13, 2025, subject to the satisfaction of customary closing conditions. Leerink Partners is acting as sole bookrunning manager for the offering. The shares described above are being offered pursuant to an automatically effective shelf registration statement on Form S-3 (File No. 333-270505) that was filed with the Securities and Exchange Commission (\"SEC\") on March 13, 2023. This offering is being made only by means of a prospectus supplement and an accompanying prospectus that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the offering were filed with the SEC on January 10, 2025, and are available on the SEC\u2019s website located at www.sec.gov . A final prospectus supplement containing additional information relating to the offering and an accompanying prospectus will be filed with the SEC and will be available on the SEC\u2019s website at www.sec.gov . When available, copies of the final prospectus supplement and the accompanying prospectus relating to this offering may also be obtained by contacting: Leerink Partners LLC, Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at (800) 808-7525 ext. 6105, or by email at syndicate@leerink.com . This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of that state or jurisdiction. Story Continues About Amylyx Pharmaceuticals Amylyx is committed to the discovery and development of new treatment options for communities with high unmet needs, including people living with serious and fatal neurodegenerative diseases and endocrine conditions. Since its founding, Amylyx has been guided by science to address unanswered questions, keeping communities at the heart and center of all decisions. Amylyx is headquartered in Cambridge, Massachusetts. Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are \"forward-looking statements\" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including with respect to the completion of the proposed offering, the anticipated closing date of the offering, the expected gross proceeds from the offering and the expected use of proceeds from the offering. No assurance can be given that the offering discussed above will be completed. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Any forward-looking statements in this press release are based on management\u2019s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include those risks and uncertainties set forth in Amylyx\u2019 SEC filings, including Amylyx\u2019 Annual Report on Form 10-K for the year ended December 31, 2023, Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024 and its subsequent filings with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Amylyx undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of Amylyx. View source version on businesswire.com: https://www.businesswire.com/news/home/20250109595584/en/ Contacts Media Amylyx Media Team +1 (857) 799-7274 amylyxmediateam@amylyx.com Investors Lindsey Allen Amylyx Pharmaceuticals, Inc. +1 (857) 320-6244 Investors@amylyx.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AMLX", "date": "2025-01-10T13:26:00+00:00", "sentiment": {"score": 0.006277516484260559, "confidence": 0.025182601064443588, "probabilities": {"positive": 0.025182601064443588, "negative": 0.01890508458018303, "neutral": 0.9559122323989868}}, "embedding": [-0.18411296606063843, -0.07384922355413437, -0.004953640513122082, 0.010840412229299545, -0.07693499326705933, 0.03446637839078903, 0.06467422097921371, 0.13376562297344208, 0.18627482652664185, 0.014899181202054024, 0.011938500218093395, 0.09832091629505157, 0.0021880948916077614, -0.05990574136376381, -0.042068615555763245, -0.029720239341259003, -0.027443088591098785, -0.01840857043862343, -0.169981449842453, 0.17192937433719635, 0.007677727844566107, -0.10647161304950714, -0.013669856823980808, 0.0037564197555184364, 0.08565174043178558, -0.13614295423030853, 0.008654344826936722, 0.034383248537778854, -0.09969811886548996, -0.09894108027219772, 0.09516939520835876, 0.1146424263715744, 0.08016102015972137, 0.005689072422683239, 0.03899312764406204, -0.0202346071600914, -0.1594466269016266, -0.05232272297143936, 0.038085684180259705, 0.0698639303445816, -0.013145988807082176, -0.04012123495340347, -0.15777723491191864, 0.016428934410214424, -0.07472126185894012, -0.10569486021995544, -0.08879179507493973, -0.004405276849865913, 0.08374510705471039, 0.0971779078245163, -0.055084094405174255, -0.019970301538705826, -0.04464292898774147, -0.001710256328806281, -0.06511588394641876, 0.04915695637464523, -0.2099214345216751, -0.034498900175094604, 0.050166055560112, 0.020754404366016388, 0.04458761587738991, -0.02596507966518402, 0.005699999630451202, 0.06087173521518707, 0.03370632976293564, 0.07452063262462616, 0.00969899445772171, -0.027649227529764175, -0.0257086381316185, -0.07487072050571442, 0.08965927362442017, -0.012210629880428314, -0.10070045292377472, 0.039212774485349655, -0.058062054216861725, 0.07928039878606796, 0.179592102766037, 0.05982546880841255, 0.09010378271341324, -0.20402894914150238, -0.04210859164595604, 0.07092108577489853, 0.010748324915766716, -0.06404516845941544, -0.026089124381542206, -0.04076438397169113, 0.12171591073274612, 0.12729424238204956, 0.1647838056087494, 0.02681308053433895, 0.04836958646774292, -0.014741905964910984, -0.0918583869934082, -0.10869110375642776, 0.016157731413841248, 0.02407766878604889, -0.11002147197723389, -0.022044287994503975, -0.016069874167442322, 0.07476796209812164, 0.08400633931159973, 0.08718421310186386, -0.030016247183084488, -0.1270066648721695, -0.10458942502737045, -0.06116703525185585, 0.059867631644010544, -0.024913419038057327, 0.012565718963742256, -0.018707191571593285, -0.14181947708129883, -0.010618560947477818, -0.041949331760406494, -0.11318147927522659, -0.048174455761909485, 0.08835934102535248, 0.03850732743740082, -0.00319792702794075, 0.2809228301048279, -0.14246147871017456, 0.06664520502090454, 0.057375747710466385, 0.07056992501020432, -0.0824240893125534, -0.05333373695611954, 0.03050372377038002, -0.08145005255937576, 9.934611894789852e-33, -0.12326619774103165, 0.0491974875330925, -0.02215152606368065, -0.035448089241981506, -0.017956789582967758, -0.021605312824249268, 0.11319088935852051, 0.01277556736022234, -0.16339518129825592, 0.06225976347923279, -0.15664595365524292, 0.08650658279657364, -0.07698671519756317, -0.01141476072371006, 0.043727077543735504, -0.07166001945734024, 0.11608731746673584, 0.028024151921272278, 0.1393929272890091, -0.014436443336308002, 0.11430224776268005, 0.03170577809214592, -0.01313645951449871, 0.015029600821435452, -0.003640826791524887, -0.049997299909591675, -0.041143372654914856, -0.0018882001750171185, 0.03118997812271118, 0.005321215838193893, 0.05379769951105118, -0.01979539543390274, 0.02767118811607361, -0.022082237526774406, -0.03384716436266899, 0.07332909852266312, -0.09431549906730652, -0.04596530273556709, 0.11481547355651855, 0.06422895193099976, -0.018336277455091476, 0.15012675523757935, -0.019547555595636368, -0.037259917706251144, -0.11911188066005707, 0.12407159060239792, -0.0358973890542984, 0.06255574524402618, 0.09051110595464706, -0.035152748227119446, -0.08132501691579819, 0.02776952087879181, -0.03239104896783829, -0.048261165618896484, -0.04096793010830879, -0.02472405508160591, -0.08786207437515259, -0.07911331951618195, 0.0742490142583847, 0.12401110678911209, 0.027523377910256386, 0.1684638261795044, -0.07518771290779114, 0.02913660556077957, -0.18475006520748138, 0.1299247145652771, -0.03213484585285187, -0.0017372728325426579, -0.0640408992767334, -0.02799638919532299, -0.09919636696577072, -0.0467730388045311, 0.18748143315315247, -0.1288033425807953, 0.006596492137759924, -0.0711541622877121, 0.003904903307557106, -0.011833840981125832, 0.1815897524356842, 0.01708788424730301, 0.023480933159589767, -0.01929640583693981, 0.028682461008429527, 0.09099087119102478, -0.019747527316212654, -0.0034351651556789875, -0.0013805832713842392, -0.019750986248254776, -0.05938517302274704, 0.05435902625322342, 0.06010152027010918, -0.07010169327259064, -0.047532327473163605, 0.09136737138032913, 0.06906361877918243, -9.13359551399299e-33, -0.025383422151207924, -0.07604297995567322, -0.055972225964069366, -0.007152944803237915, -0.058472782373428345, 0.10403576493263245, 0.1496250033378601, -0.0098164863884449, 0.02248239517211914, -0.025624964386224747, -0.01490677148103714, 0.03877527639269829, 0.00778832146897912, -0.03283391892910004, -0.039479780942201614, -0.0725061446428299, -0.023630427196621895, 0.0796411782503128, 0.06133561581373215, -0.052488308399915695, -0.04908366501331329, 0.20189739763736725, -0.025066625326871872, 0.06602970510721207, 0.06875686347484589, 0.07287605106830597, 0.015347215346992016, 0.12436066567897797, -0.018814343959093094, -0.033227767795324326, -0.02190893143415451, -0.07183995842933655, -0.1570839285850525, 0.0228397436439991, -0.10362949967384338, -0.03349795937538147, 0.08852622658014297, -0.014327983371913433, 0.010878368280827999, -0.042726557701826096, 0.09660492837429047, -0.04286676645278931, 0.17248229682445526, 0.08018029481172562, 0.08495689928531647, -0.087777279317379, 0.008745137602090836, -0.22620545327663422, 0.12240224331617355, 0.041718728840351105, -0.08745212852954865, -0.005326081998646259, 0.046870529651641846, 0.06416288018226624, -0.09857261180877686, 0.10842885076999664, 0.00031035742722451687, -0.03808323293924332, 0.0404803603887558, -0.049896128475666046, 0.08867152035236359, 0.15351393818855286, 0.06623198091983795, 0.033144883811473846, 0.16071532666683197, -0.002133413217961788, -0.03243755176663399, -0.029220959171652794, -0.007920853793621063, -0.15745729207992554, -0.057624515146017075, -0.18782928586006165, 0.06252269446849823, -0.16379988193511963, 0.044145070016384125, 0.1688859462738037, -0.0093477638438344, -0.10864345729351044, 0.00483396090567112, 0.01213030330836773, -0.04417090862989426, 0.0511019304394722, -0.10777140408754349, 0.07368192821741104, -0.020814605057239532, -0.06013673171401024, 0.08893326669931412, 0.09057076275348663, -0.009958221577107906, 0.032814063131809235, -0.06411878019571304, -0.0990343987941742, 0.06302910298109055, 0.13393262028694153, -0.06558671593666077, -9.961360092347604e-08, 0.004049449693411589, -0.026840051636099815, 0.06567949801683426, -0.10825350880622864, 0.2398974895477295, -0.022422121837735176, 0.1129593551158905, -0.010473599657416344, -0.004436386749148369, 0.09661135077476501, 0.13475196063518524, 0.1490163803100586, -0.16738083958625793, 0.01300317607820034, -0.1860584169626236, -0.006100788712501526, -0.15988335013389587, 0.005357602145522833, -0.04102133587002754, -0.09898895025253296, -0.09144836664199829, 0.10217168927192688, 0.017143484205007553, -0.052186332643032074, 0.07344111055135727, -0.06257306039333344, 0.026879504323005676, 0.1010308712720871, -0.05698195472359657, 0.09666477888822556, -0.03763031214475632, 0.011177359148859978, 0.07516643404960632, 0.02256423607468605, -0.014494471251964569, -0.0002450547181069851, -0.04698234051465988, 0.19810009002685547, 0.007695917040109634, 0.15662945806980133, -0.07083100080490112, -0.08413416892290115, 0.05891020596027374, 0.022868502885103226, 0.12069366872310638, -0.04109141603112221, -0.19277022778987885, -0.05669059976935387, 0.07078190892934799, -0.13240064680576324, 0.004614310339093208, -0.009466845542192459, -0.057935819029808044, 0.029002796858549118, -0.022469256073236465, -0.005818097852170467, -0.10869311541318893, -0.004214537795633078, -0.007750917691737413, -0.02880754880607128, -0.06409230083227158, -0.23216329514980316, 0.033465221524238586, 0.0739578902721405], "changes": {"1wk": 0.0}}, {"text": "Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock Business Wire Fri, Jan 10, 2025, 3:30 AM 4 min read In This Article: AMLX -6.30% CAMBRIDGE, Mass., January 10, 2025 --( BUSINESS WIRE )--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (\"Amylyx\" or the \"Company\") today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares are being offered by Amylyx. In addition, Amylyx intends to grant the underwriter a 30-day option to purchase additional shares of its common stock in an amount up to 15% of the shares offered in the public offering at the public offering price per share, less underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Amylyx intends to use the net proceeds from this offering, together with existing cash, cash equivalents and marketable securities, to advance preparations for commercialization and pipeline programs, for working capital and for general corporate purposes. Leerink Partners is acting as sole book-running manager for the offering. The shares described above are being offered pursuant to an automatically effective shelf registration statement on Form S-3 (File No. 333-270505) that was filed with the Securities and Exchange Commission (\"SEC\") on March 13, 2023. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC\u2019s website at www.sec.gov . When available, copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering may also be obtained by contacting: Leerink Partners LLC, Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at (800) 808-7525 ext. 6105, or by email at syndicate@leerink.com . This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of that state or jurisdiction. About Amylyx Pharmaceuticals Amylyx is committed to the discovery and development of new treatment options for communities with high unmet needs, including people living with serious and fatal neurodegenerative diseases and endocrine conditions. Since its founding, Amylyx has been guided by science to address unanswered questions, keeping communities at the heart and center of all decisions. Amylyx is headquartered in Cambridge, Massachusetts. Story Continues Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are \"forward-looking statements\" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including with respect to Amylyx\u2019 intention to conduct an offering and sale of securities, the completion of the proposed offering, the expectation to grant the underwriter a 30-day option to purchase additional shares and the expected use of proceeds from the proposed offering. No assurance can be given that the offering discussed above will be completed. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Any forward-looking statements in this press release are based on management\u2019s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include those risks and uncertainties set forth in Amylyx\u2019 SEC filings, including Amylyx\u2019 Annual Report on Form 10-K for the year ended December 31, 2023, Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024 and its subsequent filings with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Amylyx undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of Amylyx. View source version on businesswire.com: https://www.businesswire.com/news/home/20250109174588/en/ Contacts Media Amylyx Media Team +1 (857) 799-7274 amylyxmediateam@amylyx.com Investors Lindsey Allen Amylyx Pharmaceuticals, Inc. +1 (857) 320-6244 Investors@amylyx.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AMLX", "date": "2025-01-10T00:30:00+00:00", "sentiment": {"score": -0.0049222540110349655, "confidence": 0.025435874238610268, "probabilities": {"positive": 0.020513620227575302, "negative": 0.025435874238610268, "neutral": 0.9540504813194275}}, "embedding": [-0.21320763230323792, -0.07066676765680313, -0.017235495150089264, -0.03695198893547058, -0.10121877491474152, 0.031045101583003998, 0.03267449513077736, 0.11130793392658234, 0.14450940489768982, -0.009971750900149345, 0.03601035103201866, 0.11343491077423096, 0.04137810319662094, -0.06516031175851822, -0.04197917878627777, -0.0101802172139287, -0.004969340283423662, -0.009582730010151863, -0.16592636704444885, 0.19948773086071014, 0.024804454296827316, -0.10050174593925476, -0.03425681218504906, 0.019053110852837563, 0.0487055741250515, -0.1047537624835968, -0.014162812381982803, 0.0366329662501812, -0.1274036169052124, -0.10408369451761246, 0.1288149654865265, 0.10791800916194916, 0.08093529939651489, 0.011273368261754513, 0.07209089398384094, 0.02133737877011299, -0.18474051356315613, -0.07699300348758698, 0.054005637764930725, 0.0351962074637413, 0.005773906596004963, -0.09203309565782547, -0.11590979993343353, -0.0002731550484895706, -0.10024133324623108, -0.10237685590982437, -0.10726286470890045, -0.012955543585121632, 0.09447000175714493, 0.05869853124022484, -0.07266388088464737, -0.041393399238586426, -0.054721400141716, 0.027963733300566673, -0.0629146620631218, 0.09558375179767609, -0.2085493505001068, 0.021859006956219673, 0.03945541009306908, 0.008634356781840324, 0.07842778414487839, 0.030553694814443588, 0.036689966917037964, 0.06851530820131302, 0.021428098902106285, 0.0908164456486702, 0.007887205109000206, -0.00045482092536985874, -0.005235189106315374, -0.1030462235212326, 0.11010758578777313, -0.027410659939050674, -0.10136498510837555, 0.06875787675380707, -0.0752502828836441, 0.10214971005916595, 0.1598081737756729, 0.07222104072570801, 0.12641896307468414, -0.20978380739688873, -0.04214119538664818, 0.06571942567825317, -0.0006620604544878006, -0.06296044588088989, -0.07035664469003677, -0.006436143070459366, 0.10838034749031067, 0.11333576589822769, 0.20275363326072693, -0.010892721824347973, 0.07812932133674622, -0.01101257186383009, -0.1307404339313507, -0.15663352608680725, 0.05039787292480469, -0.042365662753582, -0.07484713196754456, -0.002629903145134449, -0.036777932196855545, 0.0877143144607544, 0.11716943979263306, 0.06561592221260071, -0.08605218678712845, -0.13823676109313965, -0.11232645809650421, -0.07606669515371323, 0.019479980692267418, -0.012074766680598259, 0.007701260503381491, -0.03277400881052017, -0.14638850092887878, 0.022204564884305, -0.010981405153870583, -0.11595693230628967, -0.025597695261240005, 0.11568543314933777, 0.02819380722939968, -0.013107050210237503, 0.2623392641544342, -0.18117043375968933, 0.05992535501718521, 0.055548906326293945, 0.03975335508584976, -0.12869632244110107, -0.03175591677427292, 0.020125407725572586, -0.06314904987812042, 1.0063716439340663e-32, -0.12071625143289566, 0.051511120051145554, 0.00408028531819582, -0.005179593339562416, -0.008421014994382858, -0.018839724361896515, 0.15455274283885956, -0.02704298309981823, -0.20586514472961426, 0.03444632887840271, -0.1784752905368805, 0.12138655036687851, -0.04479147493839264, -0.021286368370056152, 0.031455282121896744, -0.057686254382133484, 0.15267622470855713, 0.016846852377057076, 0.17278265953063965, -0.016610076650977135, 0.1139737069606781, 0.017973478883504868, -0.05660500377416611, 0.019629552960395813, 0.0022860628087073565, -0.06920334696769714, -0.08319714665412903, 0.019868046045303345, 0.03902296721935272, 0.014913242310285568, 0.05152066797018051, 0.009976856410503387, -0.00899042934179306, -0.0370493084192276, 0.002698637545108795, 0.08885406702756882, -0.09819120168685913, -0.07411431521177292, 0.12797288596630096, 0.04594339430332184, 0.04460493102669716, 0.1257176697254181, -0.018642913550138474, 0.013424512930214405, -0.10096774995326996, 0.17951692640781403, -0.07560672610998154, 0.10858301818370819, 0.09918282181024551, -0.011078732088208199, -0.027406007051467896, 0.04554814472794533, -0.052968829870224, -0.09266701340675354, -0.03603319823741913, 0.01745881512761116, -0.11093953251838684, -0.029763218015432358, 0.09639886766672134, 0.153883695602417, 0.01708325371146202, 0.17693114280700684, -0.11641672253608704, 0.011099986732006073, -0.16799956560134888, 0.09467889368534088, 0.005487866699695587, -0.03935613855719566, -0.05955013632774353, -0.0493503212928772, -0.09217403829097748, -0.0447622612118721, 0.20566263794898987, -0.06398706138134003, 0.0247529074549675, -0.13101381063461304, 0.02555890753865242, 0.019633285701274872, 0.09916728734970093, -0.03472999483346939, -0.010471707209944725, -0.022755201905965805, -0.0006766822189092636, 0.13435108959674835, -0.04365473985671997, -0.019882773980498314, 0.011816157959401608, -0.044902194291353226, -0.05139172822237015, 0.055532339960336685, 0.06747694313526154, -0.08989454060792923, -0.05179566144943237, 0.13148972392082214, 0.0424465611577034, -1.0155429243275788e-32, 0.011317671276628971, -0.14929324388504028, -0.0719837099313736, 0.0010577691718935966, -0.09604726731777191, 0.102998748421669, 0.1696142554283142, -0.012577811256051064, 0.043747350573539734, -0.05630791187286377, -0.010835121385753155, 0.014881735667586327, 0.05419820919632912, -0.08707284182310104, -0.04556785523891449, -0.057888515293598175, -0.05292508751153946, 0.08803915977478027, 0.03994302824139595, 0.0059265680611133575, -0.02440156415104866, 0.1723586916923523, -0.02391989529132843, 0.06565065681934357, 0.05740870535373688, 0.08031043410301208, 0.0018988922238349915, 0.13135498762130737, -0.007820885628461838, -0.07913848012685776, -0.023531926795840263, -0.04844217747449875, -0.2225569784641266, 0.05133340507745743, -0.15905752778053284, -0.06583114713430405, 0.13040336966514587, -0.06305678933858871, 0.036389607936143875, -0.06832177191972733, 0.10058516263961792, -0.03083948977291584, 0.13158954679965973, 0.15320920944213867, 0.017430000007152557, -0.11227037012577057, 0.07070963084697723, -0.19832313060760498, 0.14925546944141388, 0.023455366492271423, -0.09297004342079163, -0.02014898881316185, 0.13217265903949738, 0.06772147119045258, -0.06369008123874664, 0.1384751796722412, 0.03641391918063164, -0.05831954628229141, 0.023794040083885193, -0.027509186416864395, 0.10287720710039139, 0.181401789188385, 0.0504106730222702, 0.015871111303567886, 0.20136575400829315, 8.472427725791931e-05, -0.05041053146123886, -0.027758335694670677, 0.039367470890283585, -0.16118648648262024, -0.05351307988166809, -0.2085227221250534, 0.07252722978591919, -0.18487155437469482, 0.08157728612422943, 0.14078262448310852, -0.020723070949316025, -0.13670580089092255, -0.05318113788962364, 0.02172181010246277, -0.024848103523254395, 0.0894317477941513, -0.12219832837581635, 0.08575316518545151, -0.013504432514309883, -0.028801219537854195, 0.09718085825443268, 0.06485307216644287, 0.023928115144371986, -0.0229787640273571, -0.08579029142856598, -0.10112845152616501, 0.040101222693920135, 0.12695711851119995, -0.06245632842183113, -9.977391357551824e-08, 0.015247944742441177, -0.036206986755132675, 0.05536569282412529, -0.11522594839334488, 0.22889524698257446, 0.0311127919703722, 0.08573120832443237, -0.03932066261768341, -0.018756888806819916, 0.08090352267026901, 0.09548977762460709, 0.12573137879371643, -0.2155815064907074, -0.010981179773807526, -0.2158794403076172, -0.015952611342072487, -0.15764829516410828, -0.027780434116721153, -0.07233694195747375, -0.08477243781089783, -0.13283082842826843, 0.09178131818771362, 0.033559150993824005, -0.05393069237470627, 0.07897984981536865, -0.06636717915534973, 0.06187618151307106, 0.11571668088436127, -0.07151253521442413, 0.11662054061889648, -0.06905142217874527, -0.013117127120494843, 0.09992814064025879, 0.045703060925006866, -0.007888050749897957, -0.03440586104989052, -0.05157934129238129, 0.22760093212127686, -0.0030833075288683176, 0.122220978140831, -0.08869017660617828, -0.08716738224029541, 0.043235719203948975, 0.008588340133428574, 0.09415119886398315, -0.0084985988214612, -0.15926192700862885, -0.05170005187392235, 0.12771479785442352, -0.1069381982088089, -0.027194909751415253, -0.04680585861206055, -0.051323894411325455, 0.00562037480995059, -0.06324908882379532, 0.026655476540327072, -0.1012745052576065, -0.002835888648405671, 0.06226726248860359, -0.044850364327430725, -0.07882705330848694, -0.18950596451759338, 0.07003313302993774, 0.06526613980531693], "changes": {"1wk": 0.0}}, {"text": "Amylyx Pharmaceuticals Appoints Dan Monahan as Chief Commercial Officer Business Wire Mon, Jan 6, 2025, 5:00 PM 7 min read In This Article: AMLX -6.30% - Dan Monahan will lead the commercialization strategy across Amylyx\u2019 product portfolio, beginning with avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist for the treatment of post-bariatric hypoglycemia (PBH) - Mr. Monahan has more than 20 years of commercial leadership experience, including launching industry-leading franchises at Otsuka, Novartis, and Sanofi - Strong commercial and medical team in place for potential first-to-market launch in PBH and advancement of late-stage pipeline with the goal to bring new potential treatment options to communities with high unmet need CAMBRIDGE, Mass., January 06, 2025 --( BUSINESS WIRE )-- Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (\"Amylyx\" or the \"Company\") today announced the appointment of Dan Monahan as Chief Commercial Officer. Mr. Monahan will also join the Company\u2019s Leadership Team. Mr. Monahan joined Amylyx in January 2024, bringing more than 20 years of commercial leadership experience in the biopharmaceutical industry overseeing sales, marketing, and market access for multiple product lines. \"We are excited to announce the appointment of Dan Monahan to Chief Commercial Officer as Amylyx prepares for the first participant dosed in the Phase 3 LUCIDITY clinical trial of avexitide for the treatment of post-bariatric hypoglycemia planned in the first quarter of 2025. Dan has a strong track record of launching medicines and excels in building and leading high-performing teams that have brought new medicines to communities with high unmet needs,\" said Joshua Cohen and Justin Klee, Co-CEOs of Amylyx. \"Since joining Amylyx earlier this year, Mr. Monahan has demonstrated invaluable leadership as we work towards ensuring launch readiness for the avexitide program ahead of Phase 3 data expected in 2026 and potential future launches. We are confident that the addition of Mr. Monahan to our leadership team will play a crucial role in delivering a meaningful impact to the PBH community as we continue to move forward in our goal for avexitide to be the first therapy approved for people living with PBH.\" Throughout his career, Mr. Monahan has remained deeply committed to launching therapies that address high unmet medical needs, bringing critical treatments to those who need them most. Prior to joining Amylyx, Mr. Monahan served as Vice President, Head of CNS Marketing and Portfolio Strategy at Otsuka Pharmaceuticals, where he led the U.S. commercialization efforts for the company\u2019s CNS franchise, including REXULTI \u00ae and ABILIFY MAINTENA \u00ae , which played a critical role in treating serious mental health conditions. Before joining Otsuka, Mr. Monahan held senior leadership roles at Novartis. He led the commercial execution of the company\u2019s flagship blockbuster dermatology brand, COSENTYX \u00ae , for patients with autoimmune conditions. Prior to Novartis, Mr. Monahan spent 14 years at Sanofi in positions of increasing leadership responsibility across sales, marketing and market access. He received an MBA from Seton Hall University, and is a graduate of the United States Military Academy at West Point. Dan served as a Field Artillery Officer in the U.S. Army. Story Continues \"I look forward to continuing to collaborate with the team on advancing novel therapies from development through commercialization, with our first focus on avexitide for the potential treatment of post-bariatric hypoglycemia,\" said Dan Monahan, Chief Commercial Officer of Amylyx. \"Since joining Amylyx, I have seen first-hand both the resilience of those with post-bariatric hypoglycemia and the significant quality of life impacts that this debilitating condition can have. I am deeply motivated by the opportunity to support people living with PBH and potentially addressing the critical unmet need for a treatment option.\" In this role, Mr. Monahan will lead the Company\u2019s commercialization efforts, particularly as Amylyx prepares for the potential approval of avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist for the treatment of post-bariatric hypoglycemia (PBH). Amylyx plans to initiate LUCIDITY, a multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical trial designed to evaluate the efficacy and safety of avexitide in participants with PBH in the first quarter of 2025. About Avexitide Avexitide is an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist that has been evaluated in five clinical trials for post-bariatric hypoglycemia (PBH) and has also been studied in congenital hyperinsulinism (HI). The U.S. Food and Drug Administration (FDA) has granted avexitide Breakthrough Therapy Designation for both indications, Rare Pediatric Disease Designation in congenital HI, and Orphan Drug Designation for the treatment of hyperinsulinemic hypoglycemia (which includes PBH and congenital HI). Avexitide is designed to bind to the GLP-1 receptor on pancreatic islet beta cells and inhibit the effect of GLP-1 to mitigate hypoglycemia by decreasing insulin secretion and stabilizing blood glucose levels. In PBH, excessive GLP-1 can lead to the hypersecretion of insulin and subsequent debilitating hypoglycemic events. In two Phase 2 PBH trials, avexitide demonstrated highly statistically significant reductions in hypoglycemic events. These events can lead to autonomic and neuroglycopenic symptoms that can have a devastating impact on daily living. About the LUCIDITY Trial LUCIDITY ( NCT06747468 ) is a 75-participant, multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating the efficacy and safety of avexitide in participants with PBH. The Phase 3 trial will be conducted at approximately 20 sites in the U.S. Participants will be randomized 3:2 to receive either 90 mg of avexitide subcutaneously once daily or placebo. The trial will include a three-week run-in period and a 16-week double-blind treatment period. Participants who complete the double-blind period of the planned study will be eligible to enter an open-label extension (OLE) period with a duration of 32 weeks. The primary efficacy objective of LUCIDITY will evaluate the FDA-agreed upon primary outcome of reduction in the composite of Level 2 and Level 3 hypoglycemic events through Week 16. Safety and tolerability will also be evaluated. About Post-Bariatric Hypoglycemia (PBH) Symptomatic post-bariatric hypoglycemia (PBH) is a condition that affects approximately 8% of people who have undergone bariatric surgery, or approximately 160,000 people, in the U.S. PBH is thought to be caused by an excessive glucagon-like peptide-1 (GLP-1) response leading to hypoglycemia and impaired quality of life. PBH can cause debilitating hypoglycemic events associated with inadequate supply of glucose to the brain, known as neuroglycopenia. Clinical manifestations can include impaired cognition, loss of consciousness, and seizures. PBH is also associated with a high degree of disability that can result in major disruptions to independent living. There are no approved therapies for PBH. About Amylyx Pharmaceuticals Amylyx is committed to the discovery and development of new treatment options for communities with high unmet needs, including people living with serious and fatal neurodegenerative diseases and endocrine conditions. Since its founding, Amylyx has been guided by science to address unanswered questions, keeping communities at the heart and center of all decisions. Amylyx is headquartered in Cambridge, Massachusetts. For more information, visit amylyx.com and follow us on LinkedIn and X . For investors, please visit investors.amylyx.com . Forward-Looking Statements Statements contained in this press release and related comments in our earnings conference call regarding matters that are not historical facts are \"forward-looking statements\" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, the potential of avexitide as a treatment for PBH; and expectations regarding the timing of initiation of a Phase 3 trial of avexitide in PBH. Any forward-looking statements in this press release and related comments in the Company's earnings conference call are based on management\u2019s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: the success, cost, and timing of Amylyx\u2019 program development activities; Amylyx\u2019 ability to execute on its regulatory development plans and expectations regarding the timing of results from its planned data announcements and initiation of clinical studies; the risk that early-stage results may not reflect later-stage results; Amylyx\u2019 ability to fund operations, and the impact that global macroeconomic uncertainty, geopolitical instability, and public health events will have on Amylyx\u2019 operations, as well as the risks and uncertainties set forth in Amylyx\u2019 United States Securities and Exchange Commission (SEC) filings, including Amylyx\u2019 Annual Report on Form 10-K for the year ended December 31, 2023, and subsequent filings with the SEC. All forward-looking statements contained in this press release and related comments in our earnings conference call speak only as of the date on which they were made. Amylyx undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. View source version on businesswire.com: https://www.businesswire.com/news/home/20250106578341/en/ Contacts Media Amylyx Media Team +1 (857) 799-7274 amylyxmediateam@amylyx.com Investors Lindsey Allen Amylyx Pharmaceuticals, Inc. +1 (857) 320-6244 Investors@amylyx.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AMLX", "date": "2025-01-06T14:00:00+00:00", "sentiment": {"score": 0.5564023097977042, "confidence": 0.5658776760101318, "probabilities": {"positive": 0.5658776760101318, "negative": 0.009475366212427616, "neutral": 0.4246470332145691}}, "embedding": [-0.10148464888334274, -0.18827524781227112, 0.009508929215371609, -0.017795050516724586, -0.07666632533073425, -0.07922445982694626, -0.0017028925940394402, 0.13039879500865936, 0.0967911034822464, -0.07985856384038925, -0.14825505018234253, 0.12373226135969162, -0.013951719738543034, 0.08883854001760483, -0.02649780362844467, 0.0198153518140316, 0.08056467771530151, -0.018691468983888626, -0.1069905236363411, 0.08886587619781494, 0.0590008944272995, -0.11443227529525757, 0.022356726229190826, 0.02550787851214409, -0.08393348008394241, -0.0003421856090426445, -0.05536043271422386, -0.0408979095518589, -0.13136279582977295, -0.10031723976135254, 0.09006357192993164, 0.08047908544540405, 0.12259888648986816, -0.09454841911792755, -0.06581557542085648, 0.08411844074726105, -0.11114532500505447, -0.01645038276910782, -0.037714507430791855, -0.06531322002410889, 0.0484154149889946, -0.12364800274372101, -0.12900306284427643, -0.02150704152882099, 0.05127222090959549, -0.235011488199234, 0.01633813977241516, -0.0717860609292984, 0.05696023255586624, 0.046747058629989624, -0.13861605525016785, -0.22389717400074005, 0.01654098369181156, 0.044173743575811386, -0.03051314316689968, 0.10389271378517151, -0.08800192922353745, -0.10164966434240341, -0.012985797598958015, -0.004482293501496315, -0.06029127538204193, 0.07098569720983505, 0.030439192429184914, 0.05028427392244339, 0.04075164720416069, 0.03686947375535965, -0.015968916937708855, -0.049258992075920105, 0.06086895614862442, -0.02902425266802311, 0.042611222714185715, -0.08105605095624924, -0.07940137386322021, 0.011168666183948517, 0.06590782105922699, 0.11395123600959778, 0.14455127716064453, 0.05432961881160736, 0.22978931665420532, -0.08397595584392548, 0.06000656634569168, 0.005596541799604893, 0.05091110244393349, 0.10952477902173996, -0.06231022626161575, 0.04334728792309761, 0.04102092608809471, 0.1061345636844635, 0.062433138489723206, -0.01445191353559494, 0.06626397371292114, 0.023963112384080887, -0.03060152940452099, 0.05139453709125519, 0.02721652202308178, -0.06920751929283142, -0.05372932180762291, -0.04133682698011398, -0.0234850961714983, 0.0493352934718132, -0.07499279826879501, 0.09312446415424347, -0.03597560524940491, -0.03435666859149933, -0.1273014098405838, -0.07736945897340775, 0.05545732006430626, -0.04190495237708092, 0.059481941163539886, -0.013728167861700058, -0.12233316898345947, -0.031860239803791046, 0.05402131751179695, -0.017278436571359634, -0.11575488746166229, 0.18596670031547546, -0.16528907418251038, 0.044833600521087646, 0.2043905109167099, -0.06029552221298218, 0.03349943086504936, 0.08705388754606247, 0.042002107948064804, -0.02636251226067543, 0.13040471076965332, 0.1281135231256485, -0.13080692291259766, 9.966218733831555e-33, -0.023447008803486824, 0.03024454414844513, 0.0951336920261383, 0.10024935752153397, 0.033465638756752014, -0.0178043395280838, 0.037391744554042816, -0.06876080483198166, -0.08202175796031952, -0.06587496399879456, -0.12612605094909668, -0.013499928638339043, -0.0542525053024292, 0.18147408962249756, -0.01740560308098793, -0.0971887931227684, 0.02419913001358509, -0.022370504215359688, -0.027266785502433777, 0.006153252441436052, 0.032588206231594086, 0.0016429340466856956, -0.0603419654071331, 0.04901352524757385, 0.025451257824897766, 0.0811520591378212, 0.005127375945448875, 0.09347135573625565, 0.03562987223267555, 0.08428345620632172, -0.08541306853294373, -0.009750614874064922, -0.04377439245581627, -0.005172341130673885, -0.06970961391925812, 0.040387533605098724, -0.12383460998535156, -0.10097387433052063, 0.0477963462471962, 0.09292944520711899, -0.03332804888486862, 0.13407155871391296, -0.029719512909650803, -0.055041685700416565, 0.037303343415260315, 0.048489995300769806, -0.02177605777978897, 0.051813818514347076, 0.12076613306999207, -0.033109795302152634, 0.015404971316456795, 0.015465088188648224, -0.009402222000062466, -0.03735731542110443, -0.06473827362060547, 0.0045699914917349815, -0.05942920967936516, -0.04338628053665161, 0.1002458930015564, 0.1282554715871811, 0.007833631709218025, 0.1679038405418396, -0.04780351370573044, 0.08583232015371323, -0.02001730352640152, 0.11968609690666199, 0.06364765018224716, -0.07556084543466568, -0.10778284072875977, 0.07649488747119904, -0.06526045501232147, -0.04254787415266037, 0.13096560537815094, -0.03223172575235367, 0.04993544518947601, -0.07930833101272583, 0.06825237721204758, 0.04034124314785004, 0.08866306394338608, -0.03376482427120209, 0.03395568206906319, -0.05937263369560242, 0.005085000768303871, 0.09347979724407196, 0.013659894466400146, -0.03186654672026634, 0.014616511762142181, -0.01327506359666586, -0.11422739923000336, 0.09346957504749298, 0.07150518894195557, -0.014399670995771885, -0.022562824189662933, 0.21962910890579224, -0.021971337497234344, -1.1841782418705902e-32, 0.01121751219034195, -0.09577526152133942, 0.018126171082258224, -0.0775790587067604, -0.04709559679031372, 0.06102126091718674, 0.08689108490943909, -0.03919932618737221, 0.18061108887195587, -0.0869079977273941, 0.06645083427429199, 0.08519920706748962, -0.0167656559497118, 0.004796020220965147, -0.08141312003135681, 0.02923756092786789, -0.008936304599046707, -0.08367390930652618, -0.09674564003944397, 0.013211407698690891, 0.0742824599146843, 0.20743915438652039, -0.17081224918365479, 0.0456901490688324, -0.0030466229654848576, 0.03996451199054718, 0.15332192182540894, 0.13402019441127777, 0.05254864692687988, -0.13948744535446167, -0.11426468193531036, -0.012655218131840229, -0.22740623354911804, -0.10015574842691422, -0.09303674846887589, 0.06930098682641983, -0.03312338888645172, -0.11722274124622345, -0.07335248589515686, -0.04198961704969406, 0.08893938362598419, -0.02301119640469551, 0.0324188657104969, 0.020804408937692642, 0.06827597320079803, -0.00771417748183012, -0.04869736358523369, -0.16340065002441406, 0.09978431463241577, -0.007948016747832298, -0.13976532220840454, -0.009884631261229515, 0.009711830876767635, -0.03325069695711136, -0.016657423228025436, 0.04342510178685188, 0.055420517921447754, -0.044058844447135925, -0.032009247690439224, -0.03328818455338478, 0.010528462007641792, 0.1303427666425705, 0.16547167301177979, -0.052855633199214935, 0.03239857032895088, 0.10787405073642731, 0.08180968463420868, -0.0801069363951683, 0.037825193256139755, -0.08805127441883087, -0.0019072312861680984, -0.057194747030735016, -0.08095597475767136, -0.036163076758384705, -0.01961514726281166, 0.05023381486535072, -0.17615975439548492, -0.11494151502847672, -0.08943802118301392, -0.04002886638045311, 0.01757759042084217, 0.0020901989191770554, -0.0507948212325573, 0.06817684322595596, 0.01795123517513275, 0.034951016306877136, 0.04187522456049919, 0.07544808089733124, 0.031786419451236725, 0.0029761847108602524, -0.06723879277706146, -0.1174113005399704, -0.1241970807313919, 0.07241350412368774, 0.03979917988181114, -1.0109583570283576e-07, 0.011589488945901394, -0.054411519318819046, 0.035284899175167084, -0.05494789034128189, 0.06316327303647995, -0.013845350593328476, -0.0717335194349289, -0.021054932847619057, 0.03907442092895508, 0.10980819910764694, 0.04182429611682892, 0.21374180912971497, -0.10329287499189377, 0.0014406431000679731, -0.07229624688625336, 0.06077287718653679, -0.1381998062133789, 0.029117844998836517, -0.06089097633957863, -0.14863765239715576, -0.20832914113998413, 0.06668522953987122, 0.042151473462581635, -0.09389714896678925, 0.12567761540412903, -0.15096606314182281, 0.03542644530534744, 0.1373622715473175, -0.05832893028855324, 0.03723837807774544, -0.019044717773795128, 0.009509507566690445, -0.010256512090563774, -0.005834329407662153, 0.011584759689867496, -0.09862001985311508, -0.023975560441613197, 0.0838543176651001, 0.07978009432554245, -0.012151707895100117, -0.029480215162038803, -0.03108123131096363, 0.06006292998790741, 0.014865378849208355, 0.023983148857951164, -0.07120588421821594, -0.0971798375248909, -0.01551028247922659, 0.0632273331284523, -0.10737808048725128, 0.018017472699284554, -0.002325255423784256, -0.028442934155464172, -0.029918011277914047, -0.03537251800298691, 0.10714448988437653, -0.11297443509101868, -0.11672185361385345, -0.009904466569423676, -0.024215295910835266, 0.04396510124206543, -0.2256668210029602, 0.08774691075086594, 0.02926059626042843], "changes": {"1wk": -10.714287452030426}}, {"text": "Cerus And 2 Other US Penny Stocks With Promising Potential editorial-team@simplywallst.com (Simply Wall St) Mon, Jan 6, 2025, 8:07 PM 4 min read In This Article: CERS -3.74% DC +3.60% DC-WT -5.14% AMLX -6.30% The U.S. stock market has recently experienced a surge, with major indexes like the Dow Jones and Nasdaq showing significant gains, driven by strong performances in technology stocks and a notable rise in Bitcoin. Amidst this backdrop, penny stocks continue to capture investor interest as they offer unique opportunities for growth at lower price points. Though often associated with smaller or newer companies, these stocks can present substantial potential when backed by solid financials and sound business strategies. Top 10 Penny Stocks In The United States Name Share Price Market Cap Financial Health Rating BAB (OTCPK:BABB) $0.8224 $5.97M \u2605\u2605\u2605\u2605\u2605\u2605 Inter & Co (NasdaqGS:INTR) $4.00 $1.76B \u2605\u2605\u2605\u2605\u2606\u2606 QuantaSing Group (NasdaqGM:QSG) $3.08 $102.23M \u2605\u2605\u2605\u2605\u2605\u2605 Kiora Pharmaceuticals (NasdaqCM:KPRX) $3.63 $10.89M \u2605\u2605\u2605\u2605\u2605\u2605 ZTEST Electronics (OTCPK:ZTST.F) $0.3264 $12.01M \u2605\u2605\u2605\u2605\u2605\u2605 Golden Growers Cooperative (OTCPK:GGRO.U) $4.50 $67.38M \u2605\u2605\u2605\u2605\u2605\u2605 BTCS (NasdaqCM:BTCS) $2.74 $47.54M \u2605\u2605\u2605\u2605\u2605\u2605 Smith Micro Software (NasdaqCM:SMSI) $1.40 $24.83M \u2605\u2605\u2605\u2605\u2605\u2606 CBAK Energy Technology (NasdaqCM:CBAT) $0.9846 $88.55M \u2605\u2605\u2605\u2605\u2605\u2606 Safe Bulkers (NYSE:SB) $3.54 $377.99M \u2605\u2605\u2605\u2605\u2606\u2606 Click here to see the full list of 719 stocks from our US Penny Stocks screener. Let's explore several standout options from the results in the screener. Cerus Simply Wall St Financial Health Rating: \u2605\u2605\u2605\u2605\u2605\u2606 Overview: Cerus Corporation is a biomedical products company with a market cap of $312.00 million. Operations: The company generates $176.23 million in revenue from its Blood Safety segment. Market Cap: $312M Cerus Corporation, with a market cap of US$312 million, generates US$176.23 million in revenue from its Blood Safety segment. Despite being unprofitable, the company has reduced losses over the past five years at 17.6% annually and maintains a sufficient cash runway for more than three years based on current free cash flow. Recent developments include raising its 2024 revenue guidance and entering into an extended supply agreement with Porex Corporation effective January 2025. However, shareholders have faced dilution over the past year as total shares outstanding increased by 2.5%. Navigate through the intricacies of Cerus with our comprehensive balance sheet health report here. Learn about Cerus' future growth trajectory here. NasdaqGM:CERS Financial Position Analysis as at Jan 2025 Amylyx Pharmaceuticals Simply Wall St Financial Health Rating: \u2605\u2605\u2605\u2605\u2605\u2605 Overview: Amylyx Pharmaceuticals, Inc. is a commercial-stage biotechnology company focused on developing treatments for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases, with a market cap of approximately $282.54 million. Story Continues Operations: The company generated $196.49 million in revenue from its efforts in researching and developing therapeutics for neurodegenerative disorders. Market Cap: $282.54M Amylyx Pharmaceuticals, with a market cap of US$282.54 million, focuses on treatments for neurodegenerative diseases, generating US$196.49 million in revenue. Despite being unprofitable and having a negative return on equity of -132.24%, the company maintains sufficient cash runway for over a year and is debt-free. Recent developments include appointing Dan Monahan as Chief Commercial Officer to lead commercialization efforts, particularly for avexitide's potential approval. Collaborations like the one with Gubra A/S aim to advance novel therapeutics, while ongoing clinical trials such as LUCIDITY highlight its commitment to addressing unmet medical needs in post-bariatric hypoglycemia treatment. Click to explore a detailed breakdown of our findings in Amylyx Pharmaceuticals' financial health report. Gain insights into Amylyx Pharmaceuticals' future direction by reviewing our growth report. NasdaqGS:AMLX Debt to Equity History and Analysis as at Jan 2025 Dakota Gold Simply Wall St Financial Health Rating: \u2605\u2605\u2605\u2605\u2605\u2606 Overview: Dakota Gold Corp. is involved in the acquisition, exploration, and development of mineral properties in the United States with a market cap of $222.86 million. Operations: Dakota Gold Corp. does not report distinct revenue segments as it focuses on acquiring, exploring, and developing mineral properties in the United States. Market Cap: $222.86M Dakota Gold Corp., with a market cap of US$222.86 million, remains pre-revenue as it focuses on mineral exploration and development. The company is debt-free but has a limited cash runway of less than a year at current free cash flow rates. Recent drilling at the Maitland Gold Project has significantly extended known mineralization, revealing high-grade gold intercepts analogous to the historic Homestake Mine. Leadership changes include Robert Quartermain's appointment as CEO, bringing experience from Pretium Resources. Despite shareholder dilution and ongoing losses, Dakota Gold is advancing its Richmond Hill project towards feasibility studies in 2025. Click here to discover the nuances of Dakota Gold with our detailed analytical financial health report. Explore historical data to track Dakota Gold's performance over time in our past results report. NYSEAM:DC Financial Position Analysis as at Jan 2025 Key Takeaways Reveal the 719 hidden gems among our US Penny Stocks screener with a single click here. Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports. Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world. Seeking Other Investments? Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Jump on the AI train with fast growing tech companies forging a new era of innovation. Find companies with promising cash flow potential yet trading below their fair value . This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGM:CERS NasdaqGS:AMLX and NYSEAM:DC. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AMLX", "date": "2025-01-06T17:07:54+00:00", "sentiment": {"score": 0.8544968841597438, "confidence": 0.8653854727745056, "probabilities": {"positive": 0.8653854727745056, "negative": 0.01088858861476183, "neutral": 0.12372595071792603}}, "embedding": [-0.06082823500037193, -0.10417390614748001, -0.07934534549713135, -0.0033276185858994722, 0.022925684228539467, 0.034075044095516205, 0.011736622080206871, 0.08111381530761719, 0.017700962722301483, -0.04724705219268799, -0.1088569313287735, -0.04515260457992554, 4.516635090112686e-05, -0.03318508341908455, -0.062235672026872635, -0.10305248200893402, 0.025545775890350342, -0.016482671722769737, 0.0345199815928936, 0.015502339228987694, -0.1651909053325653, -0.07724916189908981, -0.0037736259400844574, 0.019572410732507706, 0.00014738552272319794, -4.282919690012932e-05, -0.005390486214309931, -0.00011101225391030312, -0.21635673940181732, -0.26323503255844116, -0.059824757277965546, 0.0005293507128953934, 0.08703408390283585, -0.08715540170669556, -0.06969203054904938, -0.09015343338251114, 0.11369511485099792, 0.09006274491548538, 0.02873431146144867, -0.07433857023715973, 0.011240324936807156, -0.04970785230398178, -0.04731809347867966, 0.0009097326546907425, 0.04376447945833206, -0.11341947317123413, -0.05063387379050255, -0.005691620521247387, 0.12017931044101715, 0.030197955667972565, -0.0023324773646891117, 0.08462613821029663, 0.04002911224961281, 0.06611756980419159, -0.09282192587852478, 0.051648885011672974, -0.11103059351444244, 0.032939761877059937, 0.13928303122520447, -0.061197638511657715, 0.06639598309993744, 0.01080564595758915, 0.0419473722577095, 0.0008476339280605316, 0.16427358984947205, 0.019834894686937332, -0.1426645815372467, 0.04446079581975937, -0.004757007583975792, -0.15876203775405884, 0.022103048861026764, -0.1112709641456604, -0.14120005071163177, 0.03352416306734085, -0.10648620128631592, 0.15064802765846252, 0.1387249082326889, -0.07745803892612457, 0.07319952547550201, -0.006473632529377937, -0.14001081883907318, -0.07034119963645935, 0.009885345585644245, -0.05558587610721588, -0.03975846990942955, 0.019405607134103775, 0.009209725074470043, 0.05642310157418251, 0.011087000370025635, -0.14344745874404907, 0.15661342442035675, 0.01197545975446701, -0.1627265214920044, 0.012446494773030281, 0.008685220032930374, -0.050020717084407806, -0.05519933998584747, 0.016841623932123184, -0.05170319974422455, 0.04866773635149002, 0.25689825415611267, -0.03159715235233307, -0.06074489653110504, -0.055644549429416656, -0.0076371245086193085, -0.11550682783126831, 0.1065812036395073, -0.07751834392547607, 0.06176578253507614, 0.03630319982767105, 0.04856954887509346, 0.12213575839996338, -0.1185668408870697, -0.08623869717121124, -0.123356893658638, -0.038319800049066544, -0.1643122136592865, -0.09318356215953827, 0.20588022470474243, -0.10137984901666641, 0.07837606966495514, 0.08626030385494232, -0.09573328495025635, -0.0213989969342947, -0.13854341208934784, 0.009957298636436462, -0.042446721345186234, 1.485227414435566e-32, -0.09307195991277695, 0.053977493196725845, -0.031014908105134964, -0.1290561556816101, -0.029949519783258438, 0.010106091387569904, 0.04166533052921295, -0.014831526204943657, -0.13869692385196686, -0.059782207012176514, -0.0771002322435379, 0.07399778813123703, -0.02331741899251938, -0.0038181059062480927, -0.07709804177284241, -0.2307681441307068, 0.06602743268013, -0.016762133687734604, -0.005488377530127764, -0.1376756727695465, -0.03215513378381729, 0.22106283903121948, -0.07450884580612183, 0.051559142768383026, 0.07672654837369919, -0.017451774328947067, -0.13036014139652252, -0.04250378534197807, -0.030441122129559517, 0.08102208375930786, -0.04440339654684067, 0.08285187184810638, 0.04106847569346428, 0.05052107945084572, -0.02768082357943058, -0.05873456224799156, -0.09684593230485916, -0.03861416131258011, -0.004256042651832104, -0.13021215796470642, -0.04960271716117859, 0.15068909525871277, -0.08611775189638138, 0.05637204647064209, -0.0025025182403624058, 0.06855899095535278, -0.11116698384284973, 0.12512996792793274, 0.07306569814682007, -0.1686428189277649, -0.14699344336986542, 0.005033393390476704, -0.12829333543777466, 0.09854790568351746, 0.007930404506623745, 0.001845148392021656, 0.05036972090601921, -0.16203665733337402, 0.018684491515159607, 0.09867638349533081, 0.03160509839653969, 0.19561180472373962, -0.13787397742271423, -0.055247962474823, -0.133281409740448, 0.13701358437538147, 0.048018984496593475, 0.13183623552322388, -0.14013031125068665, 0.20289218425750732, -0.05308329313993454, 0.006465410813689232, 0.2812967300415039, 0.029061583802103996, 0.13729405403137207, -0.03709832951426506, 0.025700200349092484, 0.06490439176559448, 0.019199706614017487, -0.08921383321285248, 0.06282191723585129, -0.07516379654407501, -0.00047640595585107803, 0.0641598328948021, 0.00584061723202467, 0.03232577070593834, -0.06794703751802444, 0.04591890797019005, -0.04681669920682907, -0.04775372892618179, 0.013839327730238438, 0.016675129532814026, 0.08508525788784027, 0.07488911598920822, -0.1655142903327942, -1.6202148674018618e-32, -0.050670817494392395, -0.04649379104375839, 0.007687001954764128, 0.028321947902441025, -0.010125766508281231, 0.018028372898697853, 0.030618345364928246, -0.11453987658023834, 0.04166163504123688, -0.05745138227939606, -0.02871798723936081, -0.00401128176599741, 0.03777743875980377, -0.012140139006078243, 0.011408569291234016, 0.105579674243927, -0.012448782101273537, 0.04291144013404846, -0.011002684943377972, -0.08400659263134003, -0.06888601183891296, 0.14716222882270813, -0.15082654356956482, 0.06029351055622101, 0.0428779274225235, 0.013703049160540104, -0.03783164173364639, 0.0657108873128891, 0.05145353823900223, 0.024019505828619003, -0.13221363723278046, 0.062782421708107, -0.09074841439723969, 0.1155799925327301, -0.04248414188623428, 0.01661708950996399, 0.05885187163949013, -0.020163459703326225, -0.029072778299450874, 0.0687723308801651, 0.043029215186834335, 0.03680434077978134, 0.002320684492588043, 0.08155876398086548, 0.11142946034669876, 0.04651083052158356, 0.05256001651287079, 0.03294571861624718, 0.005005441606044769, 0.1959986388683319, 0.029407693073153496, 0.009035582654178143, 0.03640506789088249, 0.14469069242477417, -0.12845191359519958, 0.05432436615228653, -0.028444163501262665, 0.11056573688983917, -0.07059746235609055, -0.03696276992559433, -0.0110996775329113, 0.1210448294878006, 0.07162384688854218, -0.0037070568650960922, 0.018155081197619438, 0.02873087488114834, -0.0916101410984993, 0.09071893244981766, -0.0681203231215477, -0.12410459667444229, 0.0035103773698210716, -0.058798715472221375, 0.16431573033332825, -0.23016710579395294, -0.07795988768339157, 0.14536559581756592, -0.013904061168432236, -0.06608971953392029, 0.016077468171715736, 0.17021042108535767, -0.03769373521208763, 0.15569967031478882, 0.08913785219192505, 0.045808661729097366, 0.057209741324186325, 0.1684727966785431, -0.07258643209934235, 0.012191140092909336, 0.009862452745437622, -0.004837480373680592, -0.05899138003587723, -0.06976982951164246, 0.04151830077171326, -0.03573860228061676, -0.07060381770133972, -1.0014193208007782e-07, 0.06073782965540886, -0.09535699337720871, -0.07324855774641037, -0.010154454037547112, 0.12111517786979675, 0.004942035302519798, 0.0881335437297821, 0.012727362103760242, 0.02970125526189804, 0.15336431562900543, 0.1408887803554535, 0.040997255593538284, -0.2194633185863495, -0.08650040626525879, -0.11790337413549423, -0.03366219252347946, -0.06410984694957733, 0.1370939016342163, 0.008118788711726665, 0.060330867767333984, 0.05720391497015953, 0.11730492115020752, 0.1270221471786499, -0.021062791347503662, -0.03632846474647522, 0.018288064748048782, -0.05789856240153313, 0.005536417942494154, 0.0863533467054367, 0.06310597062110901, -0.025472983717918396, 0.0028764819726347923, 0.055134668946266174, -0.06137719377875328, 0.15064561367034912, 0.053089581429958344, -0.06371673941612244, 0.14077362418174744, 0.03930739313364029, 0.1386909782886505, -0.0063362326472997665, -0.12316277623176575, 0.006030412390828133, 0.033007293939590454, 0.06021095812320709, -0.07659679651260376, -0.15153732895851135, 0.03504602611064911, 0.14511710405349731, -0.2087147980928421, -0.06084373593330383, -0.048726312816143036, -0.0022774694953113794, 0.020484793931245804, 0.03496765345335007, 0.11104485392570496, -0.20880091190338135, 0.03846704587340355, -0.0491427518427372, -0.007823260501027107, 0.11471672356128693, -0.2505607604980469, 0.0943932831287384, 0.17686882615089417], "changes": {"1wk": -18.87755089628354}}, {"text": "Why Is Amylyx Pharmaceuticals (AMLX) Among the Best Biotech Penny Stocks to Invest in Now? Mashaid Ahmed Mon, Dec 30, 2024, 10:52 PM 6 min read In This Article: AMLX -6.30% We recently published a list of the 12 Best Biotech Penny Stocks To Invest In Now . In this article, we are going to take a look at where Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX ) stands against the other best biotech penny stocks to invest in now. Goldman Sachs has spotlighted an often-overlooked sector poised to benefit from lower borrowing costs: biotechnology stocks. In a recent note to clients, John Flood, Goldman\u2019s Head of Americas Equities Sales Trading, highlighted biotech as an under-the-radar opportunity for those seeking to capitalize on the Fed\u2019s rate cuts. Flood noted that biotechnology stocks are uniquely sensitive to changes in interest rates as they often rely on projected future profits and are heavily impacted by the cost of capital. With little or no current profitability but significant upside potential, if clinical trials succeed, these stocks have an \u201coption-like structure\u201d that makes them particularly responsive to interest rate movements. The note also emphasized that biotech has recently seen improved fundamentals driven by positive clinical outcomes and a more favorable regulatory environment. Despite these tailwinds, biotech remains under-owned by hedge funds. According to Goldman\u2019s data, the sector ranks in the 13th percentile in hedge fund long/short positioning over the past year and just the 4th percentile over the past five years. Recent performance data supports Goldman\u2019s outlook. The iShares Biotech ETF climbed 7.7% in Q3, outperforming the Nasdaq Biotech Index and more than doubling the S&P 500\u2019s 3.2% gain over the same period. For investors anticipating a continued decline in bond yields, Goldman suggests biotechnology stocks may offer more attractive exposure compared to other rate-sensitive equity sectors, which are more dependent on broader economic growth trends. READ ALSO: 12 Best Technology Penny Stocks To Buy According to Hedge Funds and 12 Best Energy Stocks To Invest In Now . Biotech Innovations: Small Caps Lead the Way In an interview with Yahoo Finance on October 30, Stacey Sears, Portfolio Manager at Emerald Advisers, provided a comprehensive overview of the current landscape and investment opportunities in small and emerging biotechnology companies. Sears acknowledged that there has been a significant innovation in the healthcare industry, especially over the past 20 to 30 years, which was catalyzed after the decoding of the human genome in 2003, as it identified over 8,000 genetic diseases. This breakthrough provided a roadmap for researchers and scientists, leading to accelerated innovation in areas such as DNA and RNA editing and the development of treatments for orphan and rare diseases. Story Continues Sears noted that small and emerging biotechnology companies have been at the forefront of this innovation. In 2023, approximately two-thirds of all clinical trials were initiated by small and emerging biotechnology firms, and about 56% of new drug substances approved by regulatory bodies originated from these smaller companies. Sears pointed out that the sector has been underperforming over the past couple of years. This underperformance is largely due to the inverse correlation between healthcare stocks and interest rates and yields. However, she noted that the sector is now starting to see a favorable shift. Clinical advancements have continued unabated, and the pipeline of new treatments and drugs remains robust. Large pharmaceutical companies are facing a patent cliff, estimated to be around $30 billion by the end of this decade as their drugs become generic. Small and emerging biotechnology companies are seen as key sources for filling this pipeline. This situation is creating a potential M&A tailwind, as larger companies look to acquire innovative smaller firms to bolster their drug pipelines. The biotechnology sector presents a unique investment opportunity, driven by favorable interest rates, ongoing clinical advancements, and increased M&A activity. Small and emerging biotech firms, in particular, are poised to play a critical role in addressing unmet medical needs and fueling innovation in the healthcare space. Is Amylyx Pharmaceuticals, Inc. (AMLX) Among the Best Biotech Penny Stocks to Invest in Now? A medical scientist in a lab coat gazing at a microscopic view of a drug in development. Our Methodology To compile our list of the 12 best biotech penny stocks to invest in now, we used Finviz and Yahoo stock screeners to find the 30 largest biotechnology companies trading below the price of $5 as of December 26. We then used Insider Monkey\u2019s Hedge Fund database to rank 12 stocks according to the largest number of hedge fund holders, as of Q3 2024. The list is sorted in ascending order of hedge fund sentiment. Why do we care about what hedge funds do? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter\u2019s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points ( see more details here ). Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX ) Number of Hedge Fund Investors: 26 Stock Price as of December 26: $4.00 Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) is a biotechnology company dedicated to developing innovative treatments for patients with neurodegenerative diseases and endocrine conditions characterized by high unmet medical needs. The company has built a robust pipeline of promising therapies, including avexitide, AMX0035, and AMX0114. Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) is focusing on the advancement of avexitide, a GLP-1 receptor antagonist with both FDA therapy and orphan drug designations. Avexitide is being developed for the treatment of post-bariatric hypoglycemia (PBH), a debilitating condition that affects a significant portion of bariatric surgery patients. The company is on track to initiate a pivotal Phase III trial in PBH in the first quarter of 2025. This trial is designed to evaluate the efficacy and safety of avexitide in reducing hypoglycemia events, with topline data expected in 2026. The positive results from earlier clinical trials, including a 66% reduction in Level 3 hypoglycemia events and a 53% reduction in Level 2 hypoglycemia events, provide a strong foundation for the Phase III program. Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) is also focusing on the continued development of AMX0035, a novel therapy with potential applications in multiple rare neurodegenerative diseases. The company recently reported positive topline data from the Phase II HELIOS trial of AMX0035 in Wolfram syndrome, a rare genetic disorder characterized by progressive insulin-dependent diabetes, optic atrophy, and deafness. The trial demonstrated significant improvements in pancreatic function and other disease measures, providing a strong rationale for advancing AMX0035 into a Phase III program. Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) plans to meet with the FDA and other stakeholders to inform the design of this Phase III trial, with updates expected in 2025. Additionally, the ORION trial of AMX0035 in progressive supranuclear palsy (PSP) is recruiting well, and the company expects to share interim data in mid-2025. Overall, AMLX ranks 5th on our list of best biotech penny stocks to invest in now. While we acknowledge the potential of AMLX to grow, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than AMLX but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock . READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock . Disclosure: None. This article is originally published at Insider Monkey . View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AMLX", "date": "2024-12-30T19:52:44+00:00", "sentiment": {"score": 0.8894543834030628, "confidence": 0.9243065714836121, "probabilities": {"positive": 0.9243065714836121, "negative": 0.03485218808054924, "neutral": 0.04084131121635437}}, "embedding": [0.013016810640692711, -0.1425965428352356, 0.02809647098183632, -0.06874892860651016, 0.090436190366745, -0.06367723643779755, -0.05328686535358429, 0.16060613095760345, 0.18976178765296936, 0.035357777029275894, -0.19528061151504517, 0.2058713138103485, -0.037589430809020996, 0.04447106644511223, -0.12255467474460602, 0.015498962253332138, -0.023185009136795998, 0.005527453497052193, -0.08917755633592606, 0.14069914817810059, -0.04597193002700806, -0.027442827820777893, 0.18615376949310303, 0.017934776842594147, 0.02887633815407753, 0.006936671212315559, 0.0091058649122715, -0.0786687433719635, -0.24551329016685486, -0.08296304941177368, 0.014460597187280655, 0.1688723862171173, 0.026621971279382706, -0.10192215442657471, -0.09336501359939575, 0.16096346080303192, -0.005551671609282494, 0.0989728793501854, 0.11251711845397949, -0.0273809302598238, -0.024279680103063583, -0.1398160606622696, -0.08407583832740784, -0.008006822317838669, 0.05382451415061951, -0.23189957439899445, -0.006107343826442957, -0.12326271831989288, 0.1187288761138916, -0.04765833169221878, -0.1879032850265503, -0.14000695943832397, 0.03156626224517822, -0.05415431782603264, -0.05848917365074158, 0.1035858690738678, -0.07063937187194824, -0.0070090522058308125, 0.031042765825986862, 0.05076122283935547, 0.13030537962913513, -0.03853738307952881, 0.08740308880805969, -0.011947332881391048, 0.029120907187461853, -0.010498378425836563, 0.0008165659382939339, 0.1258002370595932, -0.07586626708507538, 0.01137833297252655, 0.10017554461956024, -0.04031814634799957, -0.11832232773303986, 0.016183210536837578, -0.00667668879032135, 0.04982458055019379, 0.15919849276542664, 0.18351787328720093, 0.24684059619903564, -0.03055153414607048, 0.01899028569459915, -0.09455758333206177, 0.015554001554846764, -0.05115838721394539, -0.051033347845077515, -0.010919768363237381, 0.07175523787736893, 0.02589503303170204, 0.05594954639673233, -0.014389989897608757, 0.03888687491416931, -0.02020295336842537, 0.008289058692753315, -0.03269856423139572, 0.08069989830255508, -0.06373380869626999, -0.12450488656759262, -0.058004993945360184, -0.024636035785079002, -0.045493967831134796, 0.16433361172676086, 0.03239443525671959, -0.09853587299585342, 0.027776874601840973, -0.019512344151735306, -0.18135926127433777, 0.008858371526002884, -0.03815104067325592, 0.18420302867889404, 0.05684032291173935, -0.02512696199119091, 0.1963190734386444, -0.05168614909052849, 0.010785402730107307, -0.1634177267551422, 0.14489524066448212, -0.04729828983545303, -0.07538314908742905, 0.14998963475227356, 0.015898654237389565, 0.01298216450959444, 0.061987943947315216, -0.07440085709095001, -0.08374503999948502, 0.03359561413526535, 0.04810119420289993, -0.22704365849494934, 9.689959928973055e-33, -0.04979332536458969, 0.15008839964866638, 0.027609851211309433, -0.0674896091222763, -0.10072895884513855, 0.03533928468823433, 0.06591996550559998, -0.12231288105249405, -0.1666199266910553, -0.12764064967632294, -0.2031954675912857, 0.08276316523551941, -0.06773184984922409, 0.008323811925947666, -0.011176866479218006, -0.17483428120613098, -0.07988286018371582, 0.045032158493995667, 0.04573569446802139, -0.05240834876894951, -0.11332137882709503, 0.13876484334468842, -0.06509784609079361, 0.04077811911702156, 0.021989379078149796, -0.1864873319864273, -0.10567468404769897, -0.007766355760395527, 0.04303755983710289, 0.0705365240573883, -0.06248931586742401, 0.03498440608382225, -0.04703301191329956, -0.08575107157230377, -0.03607228398323059, 0.019473180174827576, -0.0624191090464592, -0.07520482689142227, 0.07715336978435516, 0.09353674203157425, -0.07331173866987228, 0.21793663501739502, -0.0351085364818573, -0.09766305238008499, -0.015639739111065865, 0.09004079550504684, -0.02382982149720192, 0.07306337356567383, -0.12410863488912582, -0.025876369327306747, -0.14062678813934326, 0.0839461013674736, 0.0557728037238121, -0.08894709497690201, 0.03478248044848442, 0.02033127471804619, -0.14180141687393188, -0.09147639572620392, -0.06290162354707718, 0.14715562760829926, 0.04930034652352333, 0.09466565400362015, -0.08045653253793716, 0.10185740888118744, -0.169727623462677, 0.22549346089363098, 0.08859875053167343, 0.10980620980262756, -0.1587699055671692, 0.33001798391342163, -0.022184843197464943, -0.011173611506819725, 0.010607868432998657, -0.018862614408135414, -0.0015346929430961609, -0.08074124157428741, -0.07526588439941406, 0.056773655116558075, 0.04139844328165054, 0.035870663821697235, 0.13896417617797852, -0.02546706423163414, -0.12084001302719116, 0.06643864512443542, -0.04927349090576172, -0.0028756875544786453, 0.021036297082901, -0.014892740175127983, 0.032476264983415604, 0.023678340017795563, -0.024735284969210625, -0.09911224246025085, -0.01805061101913452, 0.12185463309288025, -0.012577831745147705, -1.0937130047836732e-32, -0.006000414956361055, -0.12396619468927383, 0.07084570825099945, 0.0782041922211647, -0.041347432881593704, 0.058850839734077454, 0.1705540418624878, -0.11686591804027557, 0.07277984917163849, -0.14415569603443146, -0.01541159301996231, 0.15006467700004578, -0.04325052350759506, 0.010024850256741047, -0.07457035034894943, -0.0015817219391465187, -0.07800157368183136, -0.07302811741828918, 0.01910233125090599, -0.06812881678342819, 0.012333066202700138, 0.20484980940818787, -0.13417422771453857, 0.13117599487304688, -0.1038757860660553, 0.09111499786376953, -0.1629093885421753, 0.12269953638315201, 0.020309247076511383, -0.10282175242900848, -0.07479735463857651, 0.007686823606491089, -0.17753931879997253, 0.08318822085857391, -0.0727691799402237, 0.07658813893795013, 0.013769170269370079, -0.1682860255241394, -7.198890671133995e-05, 0.0030642887577414513, 0.09785441309213638, 0.04354099929332733, -0.015890929847955704, 0.004958422854542732, 0.04589419811964035, 0.018195997923612595, -0.00947246327996254, 0.08070895075798035, 0.15587401390075684, 0.08276015520095825, -0.051670707762241364, 0.013565430417656898, 0.08943337202072144, 0.03397364541888237, -0.10273723304271698, -0.0565735399723053, 0.041753463447093964, 0.04172653704881668, -0.034505799412727356, 0.08588841557502747, -0.09128248691558838, 0.11630995571613312, 0.0671706423163414, -0.00592515105381608, -0.10110829770565033, -0.02278023399412632, 0.010190976783633232, 0.0002754572778940201, -0.06701118499040604, -0.1386587768793106, 0.06107485294342041, -0.04909669607877731, 0.06762322783470154, -0.0513429269194603, -0.04803541302680969, 0.26635342836380005, -0.09125131368637085, -0.09818227589130402, -0.15821929275989532, 0.08415891975164413, 0.09029386937618256, 0.055852241814136505, 0.042270563542842865, -0.016297174617648125, -0.02313767373561859, 0.23500165343284607, 0.057311154901981354, -0.0721498429775238, -0.0940217450261116, -0.10162481665611267, -0.06181837618350983, -0.16741961240768433, -0.04219391942024231, 0.09383165836334229, -0.024983927607536316, -1.0004243478078934e-07, 0.09676237404346466, -0.18002960085868835, 0.025845840573310852, -0.15282773971557617, 0.04836367815732956, 0.027984492480754852, 0.004215427208691835, 0.1074727475643158, 0.13134896755218506, 0.18427559733390808, 0.09553910791873932, 0.227314755320549, -0.21792839467525482, 0.10386945307254791, -0.13220015168190002, 0.03033388964831829, -0.13878735899925232, -0.014379344880580902, -0.0006627468392252922, -0.04667653143405914, -0.0928010642528534, 0.13359008729457855, 0.01115089189261198, -0.029142532497644424, 0.1333390772342682, -0.1367897391319275, 0.01779787428677082, -0.01813036948442459, 0.013079117983579636, 0.040777452290058136, -0.02771734818816185, -0.02316160872578621, 0.04994669556617737, 0.06638573110103607, -0.05274369940161705, -0.035986483097076416, 0.08834580332040787, 0.07538845390081406, 0.05748005956411362, 0.07928235828876495, 0.01809501275420189, -0.04223839193582535, -0.08900196850299835, -0.06999346613883972, -0.013288096524775028, -0.08265053480863571, -0.04634595662355423, 0.06070851534605026, 0.12343373894691467, -0.1513679325580597, 0.034292809665203094, -0.0510534793138504, 0.060662172734737396, -0.021525252610445023, 0.0031768050976097584, 0.09594012796878815, -0.2081933319568634, -0.018085313960909843, -0.052796825766563416, -0.05935560166835785, 0.0798744186758995, -0.24030202627182007, 0.21386846899986267, 0.06221429631114006], "changes": {"1wk": 2.083337601895229, "1mo": -9.895830325937451}}, {"text": "PREMIUM Amylyx Pharmaceuticals, Gubra Collaborate on GLP-1 Therapy Development MT Newswires Mon, Dec 30, 2024, 11:14 PM 1 min read In This Article: AMLX -6.30% Amylyx Pharmaceuticals (AMLX) said Monday it has entered into a collaborative research initiative wi PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AMLX", "date": "2024-12-30T20:14:03+00:00", "sentiment": {"score": 0.08433962892740965, "confidence": 0.09463757276535034, "probabilities": {"positive": 0.09463757276535034, "negative": 0.010297943837940693, "neutral": 0.8950644731521606}}, "embedding": [-0.23855441808700562, -0.24978412687778473, 0.003800617530941963, 0.09150203317403793, -0.054665885865688324, -0.07931548357009888, 0.04167034476995468, 0.08004770427942276, 0.05797663703560829, -0.09536583721637726, 0.021829525008797646, 0.2420053333044052, 0.04013923555612564, 0.05512043833732605, -0.05004177615046501, 0.06636794656515121, 0.16134051978588104, -0.1147468239068985, -0.01708093099296093, 0.07510796934366226, -0.056223005056381226, -0.05252591893076897, 0.10589785128831863, 0.008946157991886139, 0.06209415942430496, 0.048991113901138306, -0.17581452429294586, -0.16944068670272827, 0.06641881912946701, -0.11530105024576187, 0.09350874274969101, 0.054552286863327026, 0.1148916631937027, 0.041443757712841034, -0.038243621587753296, 0.013886885717511177, -0.10902631282806396, 0.003200006205588579, -0.13160161674022675, 0.01319938711822033, 0.05678296834230423, -0.14759060740470886, -0.04643693566322327, 0.058969125151634216, -0.0739162340760231, -0.20903222262859344, -0.053122881799936295, -0.02968244068324566, -0.040985751897096634, 0.13918614387512207, -0.09540575742721558, -0.39800843596458435, 0.08619426935911179, -0.0780826136469841, 0.015577436424791813, 0.03488227725028992, -0.25678467750549316, -0.13630543649196625, 0.010688652284443378, -0.023666149005293846, 0.023018650710582733, 0.030583292245864868, -0.0720343291759491, 0.09593167155981064, -0.05568249151110649, 0.14035415649414062, 0.16611266136169434, 0.036307334899902344, 0.02904207818210125, -0.20913563668727875, -0.013417278416454792, 0.039969269186258316, 0.025970671325922012, -0.034372419118881226, 0.016751833260059357, 0.09582427144050598, 0.13231413066387177, -0.02578296884894371, 0.27673840522766113, -0.03636261448264122, 0.05441701039671898, -0.07153249531984329, 0.1845993548631668, 0.05195816606283188, 0.14417265355587006, -0.10832525044679642, 0.12717166543006897, 0.17256996035575867, -0.007271807175129652, -0.20890183746814728, 0.16439908742904663, 0.10111711174249649, -0.01970597542822361, 0.012626434676349163, -0.00696119898930192, 0.046514105051755905, -0.25278785824775696, -0.17999650537967682, -0.14561042189598083, 0.04251757636666298, -0.0023013560567051172, 0.10639523714780807, 0.014721319079399109, 0.02168356627225876, -0.16487492620944977, -0.08622171729803085, -0.012153866700828075, 0.13309012353420258, -0.015552976168692112, 0.05149717256426811, -0.1240442767739296, 0.005682909861207008, 0.1287941038608551, -0.01829347014427185, -0.015746979042887688, 0.18417006731033325, -0.06808595359325409, 0.0882440134882927, 0.18659155070781708, -0.18485040962696075, 0.006051539909094572, -0.07215894013643265, -0.011750241741538048, -0.00979962944984436, 0.11473849415779114, 0.09133237600326538, -0.13435101509094238, 1.528421835977294e-32, 0.043496377766132355, 0.12914487719535828, -0.03738320246338844, 0.06565842777490616, 0.07611634582281113, 0.026625927537679672, -0.020913276821374893, -0.15178288519382477, -0.26168665289878845, -0.15349672734737396, -0.062292084097862244, 0.12460606545209885, -0.05108034983277321, 0.25560393929481506, -0.08219904452562332, 0.0028999904170632362, 0.006042716093361378, 0.09198888391256332, 0.11036146432161331, -0.0534331277012825, 0.12897080183029175, 0.03874776139855385, 0.04328354820609093, -0.017053011804819107, -0.09702207893133163, 0.14346522092819214, -0.025173556059598923, 0.034338194876909256, 0.1946898102760315, 0.012756760232150555, -0.11358503997325897, -0.06705998629331589, -0.03114488162100315, 0.04753122478723526, -0.10698568820953369, 0.2286231815814972, -0.12341400980949402, -0.09755690395832062, 0.02411578595638275, -0.009093371219933033, 0.02179233357310295, 0.1508316695690155, -0.05950433760881424, -0.13037313520908356, 0.0380295030772686, 0.020417457446455956, -0.057595524936914444, -0.08606163412332535, 0.060363709926605225, -0.0697752982378006, -0.025633616372942924, 0.15245839953422546, -0.24529844522476196, -0.014534486457705498, -0.07635533809661865, 0.18396469950675964, -0.1050742045044899, 0.07097281515598297, 0.22917664051055908, 0.008248888887465, 0.10532554984092712, 0.10304556787014008, 0.017194947227835655, -0.11710510402917862, -0.03760427236557007, 0.14257647097110748, -0.06952174007892609, -0.09764791280031204, -0.1223183274269104, 0.3280334174633026, 0.012968725524842739, -0.08375708758831024, 0.08328421413898468, -0.007097668945789337, -0.06923152506351471, -0.04423849284648895, -0.04013238474726677, -0.03594023734331131, 0.05180475860834122, 0.022122932597994804, -0.00897258147597313, 0.03398926928639412, 0.13116398453712463, 0.14394520223140717, -0.0862719789147377, -0.09073682129383087, -0.02738083153963089, -0.008338907733559608, -0.12839873135089874, 0.15010608732700348, 0.05378412827849388, 0.059595394879579544, -0.02786475606262684, 0.1262357234954834, -0.08231334388256073, -1.442052829361008e-32, -0.09547358751296997, -0.0788501426577568, 0.07718024402856827, -0.04345867037773132, -0.10509776324033737, -0.022034749388694763, 0.02143164351582527, 0.004112719092518091, 0.2876078486442566, 0.13913743197917938, 0.17308911681175232, 0.09433150291442871, -0.06984463334083557, 0.006929929368197918, 0.07893955707550049, -0.0961032509803772, 0.09499738365411758, -0.14561882615089417, -0.19399338960647583, -0.047502994537353516, 0.05250882729887962, 0.22628115117549896, -0.031270403414964676, 0.16485625505447388, 0.11060607433319092, -0.026920821517705917, 0.22502359747886658, 0.0756058394908905, 0.10806009918451309, -0.1685371845960617, -0.13818031549453735, -0.03257405757904053, -0.24227578938007355, -0.22284629940986633, -0.1144225001335144, 0.07781988382339478, 0.027714962139725685, -0.00539772305637598, -0.095249243080616, -0.1662851721048355, 0.1682109832763672, -0.024524502456188202, -0.11557608842849731, 0.013086309656500816, 0.07670734822750092, 0.06930029392242432, -0.01118091493844986, -0.0668359324336052, 0.06864094734191895, -0.08869355916976929, -0.08454009890556335, -0.016288887709379196, 0.07697895169258118, -0.08259804546833038, 0.04216762259602547, -0.012974740006029606, 0.11870366334915161, -0.15097956359386444, -0.033678632229566574, -0.03326630964875221, -0.028291888535022736, 0.11227056384086609, -0.10396653413772583, -0.18244357407093048, 0.02663860097527504, 0.0862150713801384, 0.119203582406044, -0.002948406618088484, 0.0578964464366436, 0.032886527478694916, -0.02598705142736435, 0.050052836537361145, -0.10561108589172363, -0.15730151534080505, 0.09280453622341156, 0.1035691574215889, -0.22110240161418915, -0.09402672201395035, -0.01062479242682457, -0.20415009558200836, 0.12117370963096619, 0.02254953235387802, -0.09694787859916687, -0.05824938416481018, 0.12966875731945038, -0.09999515116214752, 0.133306086063385, 0.1955045759677887, 0.14218702912330627, -0.009549020789563656, -0.1933431774377823, -0.19564852118492126, -0.18154561519622803, 0.09507552534341812, -0.05523974448442459, -9.995860494882436e-08, 0.0431828498840332, -0.0006744467536918819, 0.01904231309890747, -0.10721715539693832, 0.03787540644407272, 0.04961959645152092, -0.06241821497678757, 0.06680141389369965, -0.0037494278512895107, 0.21375146508216858, -0.012075535953044891, 0.09693983197212219, -0.058561962097883224, 0.033937010914087296, -0.1388181746006012, 0.06305278837680817, -0.08983861654996872, -0.053631968796253204, -0.010340197943150997, -0.29781922698020935, -0.08306755870580673, 0.10963841527700424, 0.0798773467540741, -0.04349270835518837, 0.09847893565893173, -0.07436853647232056, 0.09025359898805618, 0.09261228144168854, -0.011501189321279526, -0.09757683426141739, -0.09601800888776779, 0.056786227971315384, 0.037551235407590866, 0.018529457971453667, 0.010995806194841862, -0.016934961080551147, 0.13266459107398987, 0.1763692945241928, 0.1040409505367279, 0.04220789298415184, 0.040698833763599396, 0.010380817577242851, 0.1224738210439682, 0.03811003640294075, -0.15584033727645874, -0.015562889166176319, 0.0035375135485082865, -0.1768539398908615, 0.1377086043357849, 0.0934753268957138, 0.04368751496076584, -0.09500503540039062, 0.0179294366389513, -0.025837205350399017, -0.04000231996178627, 0.02412903495132923, -0.02335919439792633, -0.17803499102592468, 0.10221443325281143, -0.034946002066135406, 0.15232159197330475, -0.31643739342689514, 0.14800308644771576, -0.002777890069410205], "changes": {"1wk": 2.083337601895229, "1mo": -9.895830325937451}}]